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ABSTRACT 
As the Nigerian economy continues to grow, more multi-
national pharmaceutical companies are being attracted to this 
market. However, new companies as well as those presently 
operating in Nigeria, are faced with a fundamental problem 
typical for companies doing business in developing countries. 
This problem is lack of information important in decision 
making. 
There is a general lack of information and understanding 
of Nigeria's pharmaceutical legislations. Consequently, 
companies are forced to make many important decisions on the 
basis of lack of, or at best, incomplete information. In 
addition, little is presently known about industrial pharma-
ceutical practices in Nigeria. 
This study sought to aleviate the problem by presenting 
selected portions of Nigeria's pharmaceutical legislations 
and comparing them to United States drug laws. The two systems 
were described and explained. 
The methodology consisted of two parts. First, the study 
analyzed major sections of Nigeria's pharmaceutical laws and 
compared them to United States drug legislations. Major 
differences were identified and explained. 
The second part of the study consisted of gathering 
primary data from major United States and European pharma-
ceutical companies doing business in Nigeria . Responses 
iii 
obtained were compared to facts secured from the literature 
search. 
Although the research was exploratory in nature rather 
than conclusive, the following conditions appear to exist: 
1. There is a general lack of understanding of the 
Nigerian Food and Drug laws. 
2. The laws themselves appear to be confusing with 
numerous loopholes. 
J. The Nigerian legal environment is less stringent 
than ih the United States. 
4. Specifically, drug introduction legislation was 
found to be much less stringent in 'Nigeria than 
in the United States. 
5. Drug Registration is not of major concern to 
pharmaceutical companies in Nigeria. 
iv 
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I. INTRODUCTION 
Statement of the Problem 
All areas of the pharmaceutical industry are constantly 
reminded of the controls imposed by government. It is even 
more so in the United States where there are relatively 
more accommodating conditions such as those existing in 
developing nations of the world, particularly Nigeria. As 
manufacturers move their technology to these areas, they 
face greater challenges for which they are unprepared, and 
they are forced to make changes in their policies and stra-
tegies as conditions dictate. 
There is an abundance of research information on the 
United States pharmaceutical industry. For example, much 
research has been done in areas of manufacturing, distribution 
and promotion. In addition, these functions have frequently 
been studies in relation to prevailing legal environments 
at the time. Unfortunately, there has been a great lack 
of research data on the developing areas of the world. For 
example, this student examined the research library of one 
of the largest pharmaceutical companies in the world in 
early 1976, and found very little information on developing 
countries. The Marketing Research Division of the company 
admitted that this was the most difficult problem faced by 
its company in its operation in Nigeria. Because of Nigeria's 
2. 
status as a "third world country," researchers have ignored 
its pharmaceutical problems. Therefore, managers have been 
forced to depend heavily on their intuition in making 
important marketing decisions in Nigeria and developing 
countries. 
Moreover, it is difficult to make decisions about 
Nigerian problems based on experience in other countries 
because of its uniqueness . It is unique because of its 
position in Africa. It is perhaps the richest and certainly 
the most populous country in Africa; and it is the single 
largest potential market on that continent. For these 
reasons, it has attracted the attention of international 
marketers. As it becomes increasingly important for pharma-
ceutical companies to understand fully all aspects of the 
environment within which they must operate. 
Since these pharmaceutical companies have to operate 
within the provisions of Nigerian laws, research into the 
legal environment surrounding Nigeria's pharmaceutical 
industry will help fill the vacuum currently existing. 
By giving a description of the Nigerian market and the 
laws that guide it and relating this in terms of the American 
pharmaceutical laws, manufacturers and marketers will be 
better equiped to make good operational decisions and also 
avoid undue risks. 
On looking critically at various Nigerian laws, it can 
be seen that the basic tie between the United States as a 
former British colony and Nigeria as a more recent independent 
3. 
nation of the British Empire, exists. It is even more obvious 
in the areas of pharmaceutical laws. On the other hand there 
is a distinction between the t wo systems which is unique 
to each country. This study is designed to identify the 
similarities between United States and Nigerian drug laws 
and to help explain the differences between the t wo systems. 
In addition, the study will explore the influence these 
differing legal systems may have on the multinational phar-
maceutical marketer, 
Justification 
On beginning this study, it was felt that it would be 
difficult to compare the drug laws of the two systems mainly 
because of apparent differences in social and cultural 
histories and more obvious differences in level of techno-
log~cal and scientific development. 
However, both countries have a lot ~n common. For 
example, both countries are former colonies of the United 
Kingdom and both have operated under the provisions of the 
British Common Laws at the initial parts of their respective 
histories. Indeed, the laws of both countries today are 
based on the premise of the British Law. Both countries, 
particularly the United States, have built or are building 
8 strong free enterprise system which encourages free compe-
tition. 
Nigeria since independence in 1960, and particularly 
over the last two years has been forging a system closely 
4. 
resembling that of the United States; in education, govern-
ment, ac ience and technology. 
over the last few years, the trade between these two 
countries, each a giant in her own geographical region, is 
enormous and rising. In Nigeria, just as in the United States, 
much more money and effort are being devoted to wiping out 
poverty and disease than ever before. Massive education 
programs have been begun towards this goal, particularly 
as demonstrated in the Third National Development Plan (1975-
1980). More emphasis will be placed on preventive medical 
care and environmental health. 
It is anticipated that more laws will emerge as Nigerians 
become mor e sophisticated in their health demands. Since the 
pharmaceut i cal industry has to operate within the boundaries 
of these laws , it is essential that this study be undertaken 
i n order to identify potential problem areas. 
Objectives of the Study 
1. The study is aimed at finding the similarities and 
the differences between the pharmaceutical laws of both 
countries unde r consideration. 
2. To f ocus the attention of the international phar-
maceutical companies on the growing importance of Nigeria as 
a market f or pharmaceuticals in Africa. 
J. To point out the inadequacies in the drug laws of 
Ni geria. 
4. To identify the needs of the people in areas of 
health manpower and health facilities. 
5. To try to relate the laws enacted in Nigeria to 
the prevailing conditions at the time of enactment. 
5. 
6. To compare the impact of pharmaceutical laws in 
both countries particularly as they affect the multinational 
companies in their operations in Nigeria. 
7. To attempt to confirm what has been empirically 
known for a whiles that drug introduction legislation 
in Nigeria is much easier than in the United States. 
8. To explore the influence the differing legal systems 
may have on the multinational pharmaceutical marketer. 
Methodology 
The methodology used for this project involved two facets. 
The first activity consisted of an extensive literature 
search into the major relevant areas of the pharmaceutical 
laws of both countries. 
This was done by obtaining several relevant publications 
from the Embassy of Nigeria in Washington, Nigerian Consulate 
General in New York, the U.S. Department of State and the 
U.S. Department of Commerce. Other relevant data were obtained 
through written communication with physicians, pharmacists, 
college professors, and pharmaceutical marketing executives, 
particularly Pfizer Inc. in New York City. Further important 
materials were obtained from the U.S. Department of Health, 
Education and Welfare in Washington. 
Using the University library and the Department of 
Pharmacy Administration library as major sources of information, 
6. 
many other books and journals, articles and several publi-
cations were used as sources of comparison between the t wo 
systems under consideration. Major differences were identified. 
It should be noted that no such research of this nature 
has ever been done and the data obtained, particularly those 
from Ni geria consist of very many incomplete information 
on which empirical decisions have been made. This has made 
it necessary to design the methodology in two parts in order 
to substant iate many of the things that have been identified 
in the firs t part. 
The s ec ond activity consisted of gathering primary data 
from a sample of pharmaceutical companies. Respondents were 
the execut i ves of the international divisions of major 
pharmaceutical companies in the United States. In Nigeria, 
General Managers, Managing Directors and Directors of 
thirteen drug companies were selected. 
Cons i dering the geographical locations of the executives, 
the resourc es available to the student, in terms of cost and 
time and t he ready availability of a good mailing list for 
potential participants, it was deemed prudent to conduct 
the invest iga tion by mail questionnaire. 
Fifty-two addresses were extracted from the National 
Wholesale Druggists Association publication - 1976 Membership 
and Executive Directory. The officers addressed in the 
United State s were Vice Presidents, Presidents and Directors 
of the I nternational Divisions of the drug companies. The 
7. 
thirteen addresses in Nigeria were obtained from the U.S. 
Department of State publication of the directory of foreign 
pharmaceutical companies in Nigeria. All thirteen companies 
have headquarters in either the United States or in European 
countries. Altogether, a total of sixty-five companies 
were obtained in both countries. 
The quesionnaire was developed and a pretest was conducted 
among a carefully selected group of pharmaceutical companies 
in northeastern United States. 
The questionnaire was revised and mailed to the sample 
of companies selected for the survey. Many of the executives 
wrote back immediately: some refusing to participate in the 
study as a matter of corporate policy, others indicated that 
responding to the questions would betray vital trade secrets. 
Several calls were made to companies and reminder letters 
(see appendix) were mailed to them asking for .responses. At 
this time three more companies returned the questionnaires. 
Further efforts resulted in a return of only one more ques-
tionnaire from Nigeria--the only response received from the 
thirteen mailed to Nigeria, 
Altogether, a total of t wenty companies responded, only 
six of which filled out the questionnaire as desired--a 
response rate of approximately nine percent. 
The analysis of the responses is utilized as a finale 
to the investigation. It has been introduced at this point 
in order to prepare the reader for the format and design of 
8. 
the inves t igation. The analysis is presented in Chapter VI. 
Layout of the Project 
This study consists of seven chapters. The following 
chapter provides a background information about Nigeria 
from the colonial days through independence in 1960 to the 
present. 
Chapter III provides a profile of the health care industry 
and leads on to chapter IV which deals with the evolution 
of the pharmaceutical laws of the two countries under con-
sideration . 
The fifth chapter provides a discussion comparing selected 
areas of the Nigerian and United States pharmaceutical laws. 
Chapter VI describes the attitudes of the pharmaceutical 
companies a s found in the survey, and chapter VII summarizes 
the study's conclusion and provides suggestions for further 
research. 
II. GENERAL INFORNATION ABOUT NIGERIA 
Geography 
Nigeria, located on the West Coast of Africa, is 
bounded on the south by the Gulf of Guinea, on the north by 
the country of Niger and Chad Republic ; on the east by the 
Cameroon and on the west by the Peoples Republic of Benin, 
formerly known as Dahomey. 
It covers an area of 357,000 square miles, which makes 
it about the size of California, Nevada and Arizona combined. 
Thus it is the largest nation on the west of coast of Africa, 
and with a population of nearly 80 million, it is the most 
populous country on the continent of Africa . It is estimated 
that one out of every five Africans , south of the Sahara, is 
a Nigerian. 
Topography 
Four main topographical areas may be distinguished in 
terms of vegetat ion and climate s 
1. The hot, humid coastal belt of Mangrove Swamp, 
10-16 miles wide, 
2. The tropical Rain Forest and oil palm bush, 50-100 
miles wide north-bound , 
J. The re l a tively dry central plateau of open woodland 
and savanah, · th t t h h · covering e grea er par of t e nort ern region and 
10 . 
4. The semi- desert, bordering the neighboring country 
of Niger in the extreme north. 
Climate 
Nigeria' s t wo main seasons--the dry season and the wet 
season, can be further classified into four types of seasons, 
making it comparable to the winter , spring , summer and fall 
seasons of North America. The winter can be compared to 
Nigeria's hamattan season between the months of November and 
February. At this time it is dry , dusty and cold. In 
contrast to the American winter , it never snows in Nigeria 
and the coldest i t ever gets is perhaps as cold as a 
beautiful spring morning in the United States . 
The three months following the dry season , February, 
March and April , may be analogous to the American spring 
season. It is nice and beautiful. It is warm in the day and 
rather cool at night . Temperatures range between 65° and 70° 
in the south but down in the 50 ' s in the extreme northern 
part of Nigeria. 
The wet season begins earlier in the south in the month 
of May and overlaps into the dry season much as spring over-
laps into early summer in North America . Rainfall varies 
from 20 inches per annum in the north to as much as 150 inches 
Per annum in the south . The rains taper off around September 
and · yields to the more pleasant fall-like weather when leaves 
turn brown and wither and grounds become dry and dusty once 
again. 
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People of Nigeria 
Nigeria forms a conglomerate of heterogeneous tribal 
groups ever present in any country in Africa. Over 150 tribal 
groups are represented, with languages that differ from one 
another much as English differs from French. 
This heterogeneity has brought about serious anxiety and 
fear of domination among Nigeria's minority groups and has 
been one of Nigeria's main obstacles to forming a strong and 
united nation. Indeed, it has resulted in one of the most 
bitter civil wars ever fought on the continent of Africa. 
History of Nigeria 
The area now known as Nigeria has had a long and event-
ful history even before the colonial period. The northern 
cities of Kano, Kaduna and Sokoto have had a recorded history 
dating back to 1100 AD. Along with the Bornu Empire in the 
north east corner, the Hausa Kingdoms in the north have served 
as the important link between the Islamic haven of Mecca in 
modern Saudi Arabia and the Yoruba Kingdom of Oya, in southern 
Nigeria. 
During the 17th and 18 centuries, the effect of the slave 
trade and the inter-tribal wars was a disintegration of 
political edifice of these Kingdoms, particularly those of 
the Oyo Kingdom and the ancient Empire of Benin. The Hausa 
Emirate of Northern Nigeria was further disintegrated by the 
Fulani crusader--Usman Dan Fodio, who established the Islamic 
faith of which about 47 percent of the present Nigerian 
Population belongs. 
12. 
The arrival of Europeans in Benin in the 15th and 16th 
centuries signalled the beginning of the colonization of 
Nigeria. In 1885, the British had been widely recognized 
as an influential power and colonial owner of this part of 
Africa. In 1900, this territory came under the direct con-
trol of the British government. 
In 1914, the 100,000 square miles which was Usman Dan 
Fodio's territory was united with the southern provinces 
inlcuding Lagos Colony and called the "Colony and Protec-
torate of Nigeria." 
From 1922 to 1943 , Nigerian nationals were incorporated 
into the government as legislators and executives under the 
jurisdiction of the British Governor's Cabinet. During this 
period, successive constitutions legislated by the British 
government formulated a.federal government structure (with 
powerful federal executive and less so powerful state govern-
ments) which has persisted until today. 
Events in Nigeria since Independence in 1960 
October 1, 1960, marked the turning point in the history 
of Nigeria when it was granted full independence as a 
Federation of three disproportionate divisions of Northern 
Region (over 100,000 square miles in area and more than 50 
Percent of the population of Nigeria) ; and both the Eastern 
and Western Regions of Nigeria which when taken together, 
constitute less than 50 percent of Nigeria. 
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Admin istration of the country was handed over to the 
Northern bor n Abubakar Tafawa Balewa who became the Prime 
Minister. I n 1963 , Nigeria broke its last ties with the 
United Kingdom when it became a Republic. 
Tribal and regional tensions moun ted as politicians became 
corrupt and unresponsive to the wishes of the people. Fear 
of Ibo domination transformed into fear of Hausa domination 
and Nigeria plunged deeper and deeper into fear chaos and 
political anni hilation . Power struggle mounted at the Federa; 
level as the Ibo t ried to participate in the Federal structure 
and the Hausa r efused to share its political power. The 
leaderless Yorubas* looked on as the strife plummeted into 
a bitter and vicious struggle among the politicians . 
The c l imax was reached on January 15, 1966, when a 
dissident section of the Nigerian Army overthrew the Civilian 
government of Balewa in a coup-de-tat and brought an Ibo-born 
Major-General J . T.U . Aguiyi Ironsi to power. Ironsi abolished 
the Federal s t r ucture and inaugurated in its place a Unitary 
form of gove r nment which in essence put the leadership of the 
country in the hands of an elite few and threw the country 
further i nto uncertainty and fear as thousands of Ibos were 
murdered in protest in Northern Nigeria. 
;obafemi Awol owo, the respected Yoruba leader was jailed 
or ten years on charges of treason. 
A counter coup which catapulted a Tiv-born Lt. Col. 
Yakubu Gowen to power was implemented on July 29, 1966. 
Ironsi was killed . 
Lt. Col . Odumegwu Ojukwu, the Military Governore of 
14. 
Eastern Nigeria, himself an Ibo, saw this as a means of per-
petuating a Northern Dynasy of rulers and refused to give 
his allegi anc e to the Gowan regime. On May 27, 1967, Gowon 
promulgated a decree creating twelve states out of the four 
main regions . Ojukwu responded by proclaiming an Independent 
state of Biafra from the Eastern Region. War broke out on 
July 6, 1967 , and lasted for two and a half years. 
After nine years of rule, Gowon's regime was toppled 
in a b l oodle s s coup by yet another northern-born Brigadier 
Murtala Mohammed. Mohammed was killed in an unsuccessful 
coup attempt on February 13, 1976, and was succeeded by 
Yoruba-born Olusegun Obasanjo, who is the present Nigerian 
head of state. 
Government 
One of the most welcome acts of Gen. Murtala Mohammed 
before his assasination was the creation of a union of 
nineteen s tates* out of the twelve which Gowon had created. 
;~eca~se t here have been no significant developments in s~~~ria~s seven new states since their creation, the twelve-
thes~ s ruc ture will be used throughout the length of this 
18, 
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Nigeri a is presently under a military regime headed by 
Lt. Gen. Olusegun Obasanjo. The Supreme Military Council 
is the most powerful policy-making body in the absence of 
a legislat ure . The Federal Executive Council performs the 
role of a Cabinet . 
Except t hat decrees promilgated by the Federal Military 
Government are beyond judicial review, little has changed 
in the Federal and State judicial systems since the days 
of civilian governments. 
Barring other significant military uprising, it is hoped 
that the present government will hand over the administration 
of the country to the civilians in October, 1979, as planned. 
III. MEDICAL AND PHARMACEUTICAL PROFILE 
The People's Health 
In Nigeria where the life expectancy at birth is 39 
yearsl compared to 71.9 years 2 in the United States, it can 
be said quite succinctly that the health of the people is 
not good. 
Like in most developing countries of Africa, Latin 
America and Asia, major causes of morbidity and mortality 
are due to afflict·ion with preventable diseases such as 
malaria, tetanus, measles, tuberculosis and meningitis. 
These diseases along with small pox, 11 whose eradication 
in Nigeria by 1980 is considered feasible," dysentary and 
cholera account for 95 percent of all ill health and deaths 
in Nigeria by 1974.3 Malaria is the most notorious and re-
mains the most intractable problem because of the wide 
exposure of the population to the vector-mosquite. 
Table I is a list of Nigeria's leading causes of ill-
health and death. It represents those cases that were reported 
between 1968 and 1972. It can be seen from this table that 
much of Nigeria's ill-health and death is caused by prevent-
able diseases, most of which are under control in the 
United States. 
The figures in this table may be quite deceiving. The 
reported cases are those that occur in cities where facilities 
TABLE 1 
REPORTED CASES AND DEATHS FROM NOTIFIABLE DISEASES (1968-1972) 
1968 1969 1970 1971 1972 
DISEASES CASES DEATH CASES DEATH CASES DEATH CASES DEATH CASES DEATH 
Cholera NA* NA NA NA NA NA 11404 3095 1363 96 
Small Pox 1832 164 186 20 79 1 NA NA NA NA 
Cerebrospinal 
Meningitis 1879 214 4291 459 9712 1077 7897 886 5254 604 
Tuberculosis 8952 274 11710 214 33279 577 19344 257 17584 282 
Malaria 265908 265 369397 413 628534 1109 644494 613 798344 517 
Measles 49947 811 45139 610 53529 449 88722 785 84495 495 
Tetanus 1177 323 1689 414 3035 639 2360 462 2707 694 
*NA = Not Available . 
Source: Federal Ministry of Health, Statistics Division , Lagos, Nigeria. 1974 . 
...... 
-..J 
. 
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are usually available - and as will be seen later, the number 
of such cities is very small. Several thousand cases occur 
in villages and towns that are far from urban areas and 
hence cannot be reported. 
Shortage ef Health Manpower 
In the period between 1962 and 1972, the number of 
physicians in Nigeria rose from a scanty 1,354 to 3,112, re-
presenting a doctor to population ratio of approximately 
)1100,000 in 1962 and 51100,000 in 1972. 4 Though this 
represents an increase of more than 100 percent in the 10 
years period, it has not yet met the standard of 101100,0005 
set by the World Health Organization (WHO) for this part of 
the world. 
The situation is even more critical when consideration 
is given to the 1 , 280 or 41 percent of the physicians who 
are expatrates.6 Corresponding ratios for dentists in this 
period were 1:931,000 in 1962 to 11548,000 in 1972;* a 
ratio of much less than 11100,000 people. 
The figure for pharmacists is even more critical. In 
1962, using figures of Nigeria's Ministry of Economic 
Development, there were 583 re g istered pharmacists in Nigeria 
{including non-practicing pharmacists). Ten years later, 
there were 1,005 registered pharmacists or a ratio of 
approximately 1:100,000. 
*See Table 2. 
TABLE 2 
HEALTH MANPOWER IN NIGERIA (1962-1980) 
YEAR 1962 1972 1980 
POPULATION *N 
MILLIONS 54 69 81 
ABSOLUTE* PER ABSOLUTE* PER ABSOLUTE* PER 
HEALTH MANPOWER FIGURES 100,000 FIGURES 100,000 FIGURES 100,000 
Physician 1,354 2.5 3' 112 4.5 5,760 7,0 
Dentist .58 0.1 126 0.2 202 0.3 
Pharmacist .583 0.9 1,005 1. 5 2,025 2.5 
Nurse 7,105 13.0 15,682 22.7 16,730 33.0 
Radiologist 68 0.1 124 0.2 810 1. 0 
Med Technologist 71 0.1 240 o.4 810 1. 0 
+Population has been adjusted yearly, using 1963 as base year; 2.7 percent population 
increase per year (WHO's estimate) 1963 census (55.6 million). 
* Figures obtained from Federal Ministry of Economic Development, Statistics Division 
page 263. 
All other figures are extrapolated. 
...... 
'° . 
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Using WHO's World Directory of Schools of Pharmacy, 1966, 
a comparison can be made between the United States and African 
figures, particularly that of Nigeria. In 1963, there were 
9 ,600 pharmacists in the whole continent of Africa, excluding 
the country of South Africa. At this time African population 
was about 296 million. This represents a ratio of 31100,000. 
There were only thirteen colleges of pharmacy in the whole 
continent. 
Nigerian population at this time was 55.6 million (1963 
census). There were 484 actibe pharmacists in the country 
and one college of pharmacy. In the United States at this 
time, there were 117,897 pharmacists and a total of 76 colleges 
of pharmacy. The United States p9pulation at this time was 
about 192 million. Expressing this figure in number of 
pharmacists per hundred thousand population, Nigeria had 
three in 1962 to six±y-three in the United States in the same 
year. 
While in 1972 the number of pharmacists in the United 
States was 132,959, an increase of nearly 13 percent over 
1962 figures, and a ratio of 63:100,000; Nigerian figures 
were more than doubled to about 1,300 but remained at an 
incredibly low rate of 2:100,000. 
To bring these figures a little closer home, Rhode Island, 
the smallest state in the United States, with a population 
of less than one million in 1972 had a pharmacist to population 
ratio of 83:100, 000, even surpassing the entire United States 
ratio of 63:100,ooo.7 
21. 
Distribution of Health Manpower 
Of even greater concern is the gross inbalance in the 
distribution of the available manpower. Only 16.7 percent 
of the entire population lives in urban areas of 20,000 or 
more.8 Most of the health care personnel live in those areas. 
Indeed, in this student's home town of Ondo in Western States, 
which has a population of about 100,000, he knew of only two 
physicians. One of them was in the only General Hospital 
in Ondo and the other was engaged in private practice. There 
were only t wo pharmacies and perhaps two or three patent 
medicine stores. 
In state capitals and in larger cities there is an over-
concentration of health care personnel much as in the United 
States bigger cities. While the overall physician/population 
ratio in Ni geria is approximately 41100,000, in some states 
the ratio could be as low as less than 11100,000. Since 
there are no records of state by state distribution of all 
physicians in Nigeria, it is being assumed that the distribution 
of state-employed physicians as illustrated in Table 3, re-
flects the distribution of all physicians in Nigeria. 
Moreover, 57 percent of all physicians in Nigeria are employed 
by the states or the Federal government.9 Estimating these 
figures from those shown in Table 3, it can be seen that it 
ranges in density of 24:100,000 in Lagos State to as low as 
less th an 1:100,000 in North-Western State. It can be seen 
that th 
e six southern states of West, Lagos, East-Central, 
Mid-West, and Rivers (except the South-Eastern State) account 
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TABLE J 
DISTRIBUTION OF STATE EMPLOYED PHYSICIANS (1972) 
NUMBER OF 
(MILLION) STATE-EMPLOYED NUMBER PER+ 
STATE POPULATION* PHYSICIANS 100,000 PEOPLE 
1. WESTERN 
2. LAGOS 
J. EAST-CENTRAL 
4. NORTH-CENTRAL 
5. MID-WESTERN 
6. NORTH-EASTERN 
1. KANO 
8. BENUE-PLATEAU 
9. SOUTH-EASTERN 
10. RIVERS 
11. NORTH-WESTERN 
12. KWARA 
13.7 
1.9 
9 .23 
3.1 
3.1 
9.8 
7.2 
5.2 
4.1 
2.0 
7.1 
J.4 
494 
464 
280 
114 
106 
60 
53 
47 
46 
44 
J6 
JO 
1774 
*Ex~rapolated from 1963 Census given in Africa, No. 44, 
April, 1975. p. 2J 
+Approximate Figures. 
Source: IMS WORLD DRUG MARKET MANUAL, SEC. 14.1, 1975 
4 
24 
3 
4 
3 
1 
1 
1 
1 
2 
1 
1 
4 
I 
for approximate ly 78 percent of all physicians in Nigeria. 
According to the 1963 census, cities and towns in 
Nigeria with population above 70,000 are thirty-eight. 
twenty of these are from the Western State.10 In this 
state there is Nigeria's second most populous city - Ibadan. 
With a population of 1.5 million and also serving as the 
state capital, it has nearly all the Western State ;establish-
ments and therefore has the majority of all practicing 
physicians. Lagos, the Nigerian capital, population 1.8 
has nearly 28 percent, the highest concentration of all 
physicians in the entire Federation of Nigeria. 
The effect of these figures is to demonstrate a critical 
shortage of physicians in the six northern states of Nigeria, 
which together form more than 60 percent of the entire 
population. With the exception of North-Central State which 
has a ratio of 4:100,000, all the other northern states 
have well below the ratio of 1:100,000. Kaduna, a city of 
300,000 people has the greatest concentration of practicing 
physicians. Kaduna, of course, is the capital of the North-
Central State. This maldistribution is also true of all the 
health care personnel. It is true of dentists and pharmacists 
alike. 
The maldistribution of health personnel is not unique 
to Nigeria only. It is a problem in the United States as 
we11. Washington D.C., a city of well over 700,000 people 
had the highest concentrati·on · · · h of active physicians in t e 
United States in 1967.11 It had a physician to population 
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ratio of 318 1100 , 000. Washington D.C. of course, is the 
capital of the United States. Next to this is New York State 
with 199, Massachussetts with 181, Colorado with 168, and 
Rhode Island, wi th a ratio of 1511100,000. On the other 
end are the states of Alaska with a ratio of 69, Mississippi 
with 69; the Commonwealth of Puerto Rico with 68 and the 
u.s. outlying areas with a ratio of 611100,000. It is common 
knowledge that there is a propensity for higher concentration 
of active phys i c i ans in state capitals and of course, in 
the Federal Capital as has been seen in the Nigerian figures. 
The same is true of all other health professionals. 
Medical Facilities 
Health care centers are basically located in state 
capitals and few in the large cities. As of 1973, there were 
399 hospitals i n Nigeria, distributed disproportionately, 
just as health care personnel were. To compliment these 
facilities are 130 maternity homes and child centers; 1,600 
dispensaries which provide a combined total of 4,920 addi-
tional beds. 12 As is the case with the staffing of these 
facilities, the inherent problem of maldistribution exists. 
The rural areas are the most badly affected, and in some rural 
areas where there are facilities, services are usually "lop-
sided, leaving l arge urban areas without medical attention. 111 3 
The Third Deve l o ment Plan 1 Health 
The deve l opment plan is certainly the most comprehensive 
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of all health plans ever made in the history of Nigeria . Top 
priority is given to the "development and expansion of relevant 
training institutions in the country to ensure the adequate 
supply of the needed category of health manpower and their 
even distribution in the country." 14 An admission rate of 
about J,000 a year into Nigeria's medical schools is planned 
tor 1980. It is the government's plan to establish Teaching 
Hospitals in all state capitals in order to have an even 
deployment of physicians and the para-medical personnel 
such as pharmacists, laboratory technicians, nurses, etc. 
Emphasis will be placed on preventable health services 
such as improved sewage systems, improved drainage systems, 
and improved environmental sanitation. A total of N760 
aillion ($912 million) is budgeted for the plan period. 
lorty-one percent of this amount has been allocated for 
Federal programs and the rest for state programs. 
Seeking Medical Help in Nigeria 
Nigerians usually go through three stages in the process 
Of seeking medical attention during sicknesss 
1 . Self Diagnosis and Treatment - Self diagnosis and 
treatment involve s several mythical phenomena which are 
transfered from generation to generation. The problems 
treated in thi's f · t t h' h · manner range rom impo ency o sc izop renia. 
usually Concoctions are made from leaves and tree barks and are 
mixed with alcohol (for better extraction). The dosage 
~egimens are irregular and lack specific measures. But the 
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people have confidence in it ~nd, apparently, it works; they 
often het healed. 
2. Native Doctors (Herbalists) - The native doctors are 
in line after the process of self-diagnosis and treatment has 
failed. If the problem continues unabated, it is perhaps 
one brought on the individual by an angry god or a distant 
jealous relative. The herbalist is consulted and his re-
commendations are highly esteemed. A herbalist has been known 
to perform simple scientific experiments in the process of 
the diagnosis of diabetes mellitus. He asked his patient to 
urinate in one corner of his room, after a period of about 
10-15 minutes, he would check the spot for ants. A cluster 
of ants on the urine would suggest the presence of sugar in 
the urine. He would then taste the urine to confirm the 
experiment. 
The herbalist is usually not educated, but has some 
attributes which are essential for the job. It includes, but 
is not limited to the following: religion, sacred and acrobatic 
dances, simple magical charms, incantations, drug lore, 
mythology and etc. Bundukamara15 likens these qualifications 
to those of the primitive medicine men of the Navaho Indians 
of the South-West United States. The more charms and incan-
tations the herbalist knows, the more likely he is successful 
in his practice. A long period of apprenticeship is a must 
fer the potential herbalist. He associates with an older and 
•ore experienced herbalist and runs errands and does a lot 
Of the compounding of the various ingredients in his pre-
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ceptor's "pharmacopoea". In this process, he picks up the 
incantations and charms that form a major integral part of 
the medicinal practice, and soon he becomes a herbalist him-
self. According to Kouadvi,16 " ..• the art of healing is 
limited to various categories of people who inspire respect, 
tear and mistrust, '1 with reference to the herbalists. These, 
in a few words, explain the qualification of the Nigerian 
native doctor. 
Kouadvi's list of African Traditional Pharmacopoea con-
•ists of the following: 
(a) Simple or compound species - made with mixtures of 
leaves or barks; 
(b) Packages - made of leaves of trees or papers; 
(c) Plant ~ juices - obtained by grinding after squeezing 
fresh plants; 
(d) Alcolature - obtained from roots and barks which 
have been macerated in gin, rum or any other alcohol; 
(e} Pellets and pill - pounded fresh leaves rolled into 
balls of desired size and dried; 
(f} Liniments - made of oil from palm trees, cocoa, sesame; 
(g) Throat sashes - mixture of astringent plants or an 
infusion of such plants. 
Contusion, grinding, separation, squeezing, torrefaction and 
carbonization are used in the process of compounding these 
terials.l? Scientific accuracy is not necessary and thera-
P9Utic application of these materials vary depending on the 
ntu·t· 1 ion of the herbalist. 
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A sick man, down for example ranging from simple bacterial 
infection to complications of cancer, is treated in part, with 
rituals such as invoking the power of the gods , and asking 
the patient to repeat certain incantations three, seven or 
twenty-one times, depending on the seriousness of the disease. 
Directions to patients often inlcude a list of taboos, the 
violation of which may nullify the effect of the preparation. 
This is analogous to the practice of the Cherokee Indian 
tribe of North America, whose taboo list include the following: 
• ••• one must not touch a squirell , a dog, a cat, a mountain 
trout, a woman •... " l 8 
Eric Stone's19 classification of American Native "materia 
medica" into three categories can be applied to Nigeria 's 
medicine men of today: 
1. Substances effective as carriers of devine power -
for example, the Apache relied on a piece of cholla 
cactus hung around the neck to protect children 
against sickness, just like the American grand-
mothers used a tiny bag of asafoetida to protect 
their children. 
2. Substances upon which "God" had put a sign as to 
their intended usefulness - for example, the 
Hopi used hair-like clematis fibers to treat 
falling hair, and dusted ashes on burned skin 
as a healing protective . 
3. Substances used for their physiologic actions 
(empirically discovered) - the Missouri River 
tribe used wild mint as a carminative and 
magnesia salt found in mineral springs as a 
laxative. 
The power of the Nigerian native doctor is immeasurable. 
Stor· ies have been told of persons whose magical power makes 
them "disappear" at the sound of a gun shot, military officers 
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who can catch f lying bullets and executives whose jobs become 
•secure" after a visit to the native doctor. Judges are said 
to have slept and snored in the midst of complicated criminal 
trials as a re sult of magical charms cast on them by the 
accused. Such court cases are said to have been dismissed 
after several such incident! 
Belief i n the native doctors is diminishing gradually as 
Nigerians are becoming increasingly aware of the scientific 
approach to disease healing . Less confidence is placed on 
the native doc t or ' s empirical approach. Illness is blamed 
less on the doing of distant relatives or jealous subordinates. 
More and more people are turning away from them as Nigerian 
Lawmakers are pondering on what to do with them. There have 
been calls fo r t he legislators to ban them from practice. 
Opponents have argued that this would be disastrous especially 
tor people in t he rural areas where physicians are inherently 
absent. Others have called for their certification. But it 
is difficult to certify a native doctor ' s credential without 
baving a measuring yardstick on his abilities and capabilities. 
Many scientists, including Dr. Adeoye Lambo,20 an 
•inent psychi a t rist with international repute, have called 
for a joint venture between the native doctors and Nigerian 
•cientists in r esearch into African Medicine . The Nigerian 
Association of Medi· cal ( Herbalists a group representing the 
l'll.tive doctors) has siad that it would like to see the develop-
ent Of tradit ional medicine side by side with modern methods 
Ila in China and Egypt. It said that a ban on their practice 
• will cause hardship to millions of Nigerian patients 
••• 
the death rate significantly." 21 This and increase 
29. 
statement is further reinforced by the statement of the former 
Mid-Western State Governor - Brigadier Ogbemudia, who urged 
the Nigerian Medical Council to conduct research into 
tradtional medicine. The North-Central State Governor also 
supported the idea of conducting research into local herbs.22 
While the traditional healers occupy a very unique 
position in Nigeria's health care system, the prognosis for 
their continued existence in this role is not very good. 
Gradually their role is being phased out; not by the Govern-
ment (which is a more effective way but certainly more con-
troversial2, but by the people themselves who have identified 
a better and less primitive system. Thus, the elimination of 
their role from the health care team is only a matter of time. 
3. Pharmacists and Physicians - The third and final . 
step in seeking medical help in Nigeria is a visit to the 
Pharmacist or the physician. The position of the pharmacist 
in the health team is very important. He is a "Quasi-doctor"~ 
just as Bundukamara23 pointed out. He is sandwiched between 
the practice of pharmacy and the practice of medicine, 
whereas, in the United States, the pharmacist serves as a 
•iddleman between the patient and the physician. As far as 
drug consumption is concerned, the relationship between 
P8.tients/pharmacists/physicians in Nigeria is a rather more 
8Ubtle one. 
Most patients do not see a pharmacist after a visit to 
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the physician. A lot of them do not see the physician after 
a visit to the pharmacist either. Physicians dispense their 
own prescriptions . 24 Several reasons can be conjectured for 
this practice: 
1. Physicians dispense their own prescriptions because 
of the profit obtained from selling those drugs 
themselves; 
2. Because of the esteem derived from doing so - most 
Ni gerians believe in the physicians power of healing 
and cannot conceive of the idea of going to a third 
party to obtain their medicines; 
J. Patients usually feel that physicians have not done 
their jobs properly if they do not receive medication 
from them; 
4. Physicians have 100 percent control over their patients. 
Other reasons would shed some light on the practice of some 
of the Nigerian pharmacists: 
5. Most physicians believe that their prescriptions are 
dispensed by persons other than pharmacists whose 
" •.. knowledge of medicine is only limite to the 
name of the package or the bottle. 11 25 
6. Because of the 11 ••• unscrupulous pharmacists who 
would sell deadly and untried drugs which they 
profess to be potent and efficaceous at factastic 
prices. 0 26 
7. Some physicians have argued that" ... they would 
rather dispense than send prescriptions to shop 
assistants .... Since pharmacists are not there 
most of the time in the part-time shops ... 11 27 
If these charges are true, it is a serious indictment on 
he integrity of many Nigerian pharmacists. 
Looking at the other side of the issue, pharmacists in 
Nig · 
eria may be engaged, to some extent, in the practice of 
•dicine. 1 n a Lagos University Survey of 1,000 consumers, 
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30 percent acquired their last medication from a pharmacist 
without a phys i cian ' s prescription.28 Apparently , pharmacists 
prescribe drugs to their patrons in contravention of legal 
dictates and ethical standards. It is unfortunate that the 
study failed to identify what category of drugs this fraction 
of those questioned have obtained from their pharmacists. 
This survey, however , supports pharmacists' claims of pro-
fessional competence , and their desire for better recognition 
of what their capabilities are . Apparently, the JO percent 
who responded obtained relief from whatever patholog ic pro-
blems they had, or they would have had to go to the physician. 
The syrvey als o underscores the importance of the pharmacists 
in a developing country where the economy cannot affort the 
"luxury" of physician attention . 
The physicians ' charges against pharmacists - that 
pharmacists do not dispense the prescriptions sent to them, 
is also a serious issue. The implications are obvious. 
Pharmacists simply keep their pharmacies open and leave the 
premises to be manned by non-professionals. Physicians 
resent this pr actice and therefore stock their offices much 
as pharmacists would stock their pharmacies, and dispense 
their own prescriptions in direct competition with pharmacists. 
This raises the question of the integrity of the physicians 
too. 
The possib ility of prescribing and dispensing only 
drugs that are s t ocked exists; in essence, setting up a 
superficial f ormulary. It · t k h th t d is no nown w e er or no , an 
J2 . 
in what rate if at all, physicians direct patients to phar-
macists to obtain drugs that the physicians do not normally 
stock. It has been suggested however , that the lust for 
money may i nde ed force the physician to limit his prescribing 
habit only to drugs that are stocked whether or not they are 
'the most appropriate for the disease diagnosed . 
All this cont roversy revolves around a basic flaw in 
the Nigerian system : 
1. The enforc ement mechanism of laws enacted regarding 
the control of the professional practices of these 
groups is nothing but an illusion. 
2. The laws enacted are not adequate for the control of 
these professions . 
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IV. EVOLUTION OF PHARMACEUTICAL LAWS AND PRACTICE: 
UNITED STATES AND NIGERIA 
Just as t he American criminal and tort laws are an out-
growth of the British Common Laws. so are the pharmaceutical 
laws enacted i n Nigeria. in some ways an outgrowth of British 
pharmaceutical laws. 
Nigeria enj oys the unique opportunity of not only 
emulating the British system, but emulating the American 
eystem as well i n their judicial systems. West Africa1 
reported that the present draft of the Nigerian Constitution--
due to be ratified by a Nigerian Constituent Assembly in 1978, 
will in theory. be similar in many ways to the United States 
Constitution. Ni gerian pharmaceutical laws have followed 
this pattern consistently. 
Evolution of Pharmaceutical Laws in Nigeria 
Richard Z. Bailey was granted a license to open a pharmacy 
1n Lagos in 1887 , This, according to Egboh2 marked the entry 
into Nigeria of European Pharmacy . Thelaw requiring examination 
and l' 3 icensure of pharmacists was enacted in London in 1617 
and apparently was found fit for Nigeria, a country witnessing 
the entry of · its first pharmacist. 
Just as pharmacists served a period of apprenticeship 
llnder the physic ians in the United States, the Nigerian 
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"dispensers" of this time served under the supervision of 
the British Medical Officers. 
Pharmacy Ordinance No. 8 of 1902 marked the beginning 
of pharmaceutical regulations in colonial Nigeria. It was 
designed to control the sale and distribution of drugs along 
the coastal areas of Nigeria. The term "dispensers" was 
discarded in the Act of 1923, when the term "druggist" was 
adopted. It was thought to be more prestigious and more 
reflective of the three year training course started at the 
newly constructed School of Pharmacy in Yaba, Lagos. 
The Poison and Pharmacy Act of 1927 provided for ins-
truction 0f students for the "Dispenser's Certificate". 
Further studying would earn a Chemist and Druggist Diploma. 
Examinations were conducted by the Medical Supervisory Board. 
Just as there was controversy over the professional 
atatus of pharmacists in Britain in the 1600s and 1700s, 
there was also a delay in the recognition of pharmacists 
in Nigeria as professionals. Until 1969, remuneration of 
Jtharmacists was based on a classification of pharmacy at a 
ub-professional level. This was changed in 1969 on the 
recommendation of Professional Grading Team commissioned by 
Nigeria's Military Government. 
In 1936, the Poison and Pharmacy Ordinance was enacted 
bring pharmaceut ical education in Nigeria in line with 
'\hat of the United Kingdom. The syllabus and curricula of 
he Ch · t emis s' and Druggists' Diploma were standardized and 
body known as the Pharmacy Board of Nigeria was created 
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out of the representatives of the Nigerian Union of Pharmacists 
and the Association of Dispensers. This body is now known as 
the Pharmaceutical Society of Nigeria. 
The 1936 Act also set up rules regarding the granting 
of licenses for thesale of patent and proprietary medicines, 
and also required the issuance of the Missionary Permits for 
dispensers who practice at missions. This Act reflects the 
level of sophistication of the Nigerian Pharmacy then and sub-
sequent Acts are even more comprehensive, particularly in 
dealing with the expanding level of pharmaceutical service 
in Niger is. 
In 1946, there was an ammendment to the 1936 Ordinance 
repealing that requirement for the dispensers examination 
and strengthening the establishment of the Pharmacy Board of 
Nigeria with the medical adviser as the Chairman. It also 
gave control and disciplinary powers over the practice of 
Pharmacy in Nigeria to the Board. 
Following the 1946 Act came the Ordinance of October 1960, 
ihe year of Nigerian Independence, which is termed the Poison 
!Dd the Pharmacy Act of 1960. 
What Egboh4 termed the "magna carta" year of Nigerian 
Pharmacy was in 1964 when the control of the profession was 
118.de the responsibi lity of the Pharmacy Board of Nigeria. 
the chairmanship of the Board was handed to the Chief Pharma-
cist of the Federation of Nigeria. The Pharmacy Act of 1964 
•lso made provi· s i· ons for th · · f '' h t t ' e determination o w a s andards' 
•f knowledge and skills are expected" from prospective pharmacists. 
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The year 1966 marked a turning point in Nigerian history 
as the Army took over the adminstration of the country. All 
enactments heretofore called Ordinances are known as Decrees. 
Most of what Nigeria now has as drug laws were enacted 
during some eleven years of military rule in Nigeria. The 
Indian Hemp Decree is perhaps the most stringent law on book 
in Nigeria. It was promulgated as a result of growing use of 
JIB.X'ijuana in the country. It decrees a t wenty-one year jail. 
or death sentence for the possession or intent to distribute 
marijuana in Nigeria . 
The Amphetamines Decree of 1968 was enacted to control 
the use of amphetamines and amphetamine-like drugs in Nigeria. 
It also prohibits the use of and imposed strict penalty for 
the use of Lysergic Acid Diethylamine (ISD) and some other 
narcotic drugs. 
The most comprehensive law enacted to control the 
iaharma.ceutical industry in Nigeria is the Food and Drug Decree 
Of 19?4. This law reflects the trend in times as it deals for 
the first time ever with the control of manufacture of drugs . 
~t also deals with various aspects of drug marketing which 
eretofore have not been dealt wi th. It deals with the ins-
pection of the premises used for manufacturing drugs. and for 
the f' irst time, there are provisions for the control of 
lla.nutacture, distribution and marketing of devices. 
Evolution of Pharmaceutical Laws in the United States 
Pharmaceutical laws were not enacted in the United States 
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til the "Virginia Act for the regulation of the fees and 
llccounts of the practicers of physics"5 was passed in 1736. 
this time, the rates allowed those persons "who have 
atudied physic i n any university and taken any degree therein 
" e about t wi ce as high as the fees allowed: •• wer " ... 
surgeons, and apothecaries who have served apprenticeship for 
'hose trades ... "6 For the protection of patrons against 
high fees charged by physicians and apothecaries at that time, 
the law stressed t he need for complete disclosure of all drugs 
spensed to the patients and also that moneys charged must 
reflect the quant ities of drugs dispensed. 
At about the same time, the Massachussetts Medical Society 
fetitioned the l egislature to "prohibit the sale of bad or 
adulterated drugs." Louisiana and North Carolina laws 
established the princ iple of licensure as prerequisite for 
e practice of pharmacy. In 1821, the Philadelphia College 
o:t Pharmacy wa s established as a protest against the encroach-
llent of the medical profession in the profession of pharmacy. 
The first s ecretary of the American Pharmaceutical 
sociation (APHA) , John M. Maisch, suggested uniform state 
)iilarmacy laws i n 1868, and in 1900, pharmacist/lawyer James 
K Beal vigorously promoted the passage of such laws. 
As retail pharmacy expanded in the U. S ., so did i nterest 
in drug manuf acturing; and as new drugs were introduced into 
'1le Am · erican market , it became necessary to enact laws to 
b the laissaz-faire attitudes among manufacturers and 
•llers f . 0 proprietary medicines. It was necessary t o enact 
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the fure Food and Drug Act of 1906 which was designed to enact 
penalties for certain types of misbranding and adulteration . 8 
!he disaster of the "elixir sulfanilamide" of 1937 which 
killed at least 73 people, and the public demand for protection 
against the unscrupulous practices of the pharmaceutical 
industry, force d the congress to pass an even tougher leg is-
lation in 1938. This was the Food, Drug and Cosmetic Act 
which imposed certain restrictions on the marketing of "new 
drugs". It a lso gave the Federal Government jurisdiction 
over medical devices and cosmetics . At the same time, congress 
passed an ammendment to the Federal Trade Commission Act in 
order to put effective control over false advertising of 
foods, drugs and cosmetics and over deceptive and unfair 
trade practices . 9 
The thalidomide episode of congenital malformation re-
ported in Europe and Canada in 1960 and 1961 precipitated 
the passage of t he Kefauver-Harris Ammendment to the 1938 
Law. This ammendment added the safety clause to the efficacy 
requirement for a new drug to be approved for marketing . It 
is perhaps the single most effective legislation passed in 
Congress to control the introduction of new drugs into the 
United States market. It curtailed, rather sharply, the 
introduction of new drugs in the United States. 
The Food and Drug Administration (FDA) imposes strict 
req · 
uirements on drug companies before drugs can be approved 
tor marketing by the following : 
1. requiring extensive testing to demonstrate safety 
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and effectiveness. 
2. requiring that companies continue to submit periodic 
reports on their drugs during marketing. 
3. putting restrictions on advertising and other forms 
of promotion during marketing.10 
Analysis of Significant Developments 
With the exception of the Food and Drug Decree of 1974, 
no other laws of significance have been enacted to control 
the practices of the drug manufacturers in Nigeria . It was 
not necessary to do so because of the absence of drug manu-
facturers in Nigeria. This parallels the situation in the 
United States during the colonial period under the United 
Kingdom. Drugs generally were imported from Great Britain, 
and what was right for the U.K. at that time was considered 
right for her possessions. 
However, since independence in 1960, several British 
companies, such as Glaxo Pharmaceuticals, May and Baker, 
started to do some manufacturing in Nigeria. During the mid-
1960s, some American companies started a small scale manufac-
turing in Nigeria, and it thus became necessary to set up 
guidelines . for the operation of their business as it impacts 
upon public health and safety. 
The evolution of pharmaceutical practice and laws has 
taken similar paths in both countries. The pharmacy profession 
was subJ.ected to intense pressure by the medical profession. 
Although Nigeria witnessed the entry of its first 
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pharmacist nearly 100 years ago, it did not recognize pharmacy 
as a profess i on until 1969. Even now in the United States, 
the status of the pharmacists is under challenge . The United 
states pharma cist during the 1800s became militant enough 
to break away f r om the shadows cast on them by the medical 
profession to form the first professional organization --
the American Pharmaceutical Association . 
In most cases , drug laws have eveolved in the United 
tates throgh a national or international tragic experience 
from drug toxic ity or adverse effects. In Nigeria, particularly 
before the military era , drug laws developed through evolu-
tionary mens and through international influence. But 
since the begi nning of military rule in 1966, drug laws have 
evolved through radical efforts of Nigerian legislature, and 
aore important ly , from examples set by other nations, parti-
cularly the United States. 
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V. GOVERNMENT CONTROL 
A Comparison of Selected As~ects of United States and 
Ni erian Pharmaceutical Laws. 
As consumption of drugs rises each year in Nigeria, and 
as the nation' s economy develops in massive proportions (per 
capita consumption of drug is still about $1.00 compared to 
$JO.CO in the United States in 19751 and the Nigerian Gross 
National Product (GNP) was about $27 billion2 compared to 
United States $1,400 billion in 1975), more and more pharma-
ceutical companies are finding their way into the Nigerian 
market. And as the scramble for the Nigerian market continues, 
the Nigerian Government is imposing more restrictions on 
business activities of foreign companies in Nigeria. 
The Indigenization Decree Ammendment of 19773 classified 
all business activities into three categories: 
1. Schedule I: Those business which are exc~usively 
reserved to Nigerians. 
2. Schedule II: Those business which allow 40 percent 
foreign participation and 
J. Schedule III: Those business that allow 60 percent 
foreign participation. 
The Pharmaceut ical industry is grouped in Schedule III. 
In the United States, several government agencies are 
given the statutory authority to control the distribution of 
drugs. Chief among these is the Food and Drug Administration 
(FDA) which controls the marketing and promotion of pres-
cription drugs. It also shares in the responsibility for the 
control of the promotion of over-the-counter drugs with the 
Federal Trade Commission (FTC). 4 The FDA inspects manufac-
turing facilities, reviews and approves or denies the clinical 
testing of drugs prior to marketing; limits the therapeutic 
claims for products and monitors advertising. Recently the 
FDA embarked on a major scientific examination of the medical 
credentials of prescription drugs on the market.5 Other 
government agencies involved in the control of the distri-
bution of drugs are: The Drug Enforcement Administration 
(DEA) which is responsible for control of drugs with misuse and 
abuse potential, and the Division of Biologic Standards (DBS) 
which controls the distribution of Biologics. 
In Ni geria , there is only one agency designated by the 
•ilitary government which controls the activities of the drug 
industry in areas of manufacturing , distribution, promotion 
and advertising . The agency is the Food and Drug Advisory 
ouncil (FDAC). Its function is to formulate guidelines in 
the following areas: 
(a) Determination of adulterants 
(b) Packaging, labelling specifications and sale 
(c) Preventing the consumers and users from being misled 
by manufactures as to the value of the ingredients 
(d) Laying down standards to be attained by articles 
(e) Importation 
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(f) Manufacture, preparing, packing, storing and testing 
of articles 
(g) Maintenance of books and records as prescribed 
(h) Application and issue of certificates to qualified 
manufacturers and conditions required of the premises 
where manufacturing will be undertaken 
(i) Acquisitions of test batches of drugs manufactured 
to ascertain their suitability and paying the 
prescribed fees 
(j) Mode of sampling reporting 
(k) Exemption of certain materials from the provisions 
of the Act 
(1) Prescription of the forms to be used 
(m) Conducting analysis and prescribing fees for such 
analysis 
(n) Distribution of samples of any drug 
(o) Ammendments of the schedules as may be necessary 
(p) Prescription of other things for the execution of 
this Act . 
These functions are shared among other sub-agencies under 
The sub~agencies are as follows:6 
1. Federal Manufacturing Laboratory 
2. The Federal Medical Stores, Oshodi 
J. The Kano Airport 
4. Pharmaceutical Registry and 
5. The Inspectorate Unit. 
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The Federal Manufacturing Laboratory does not presently 
_.nufacture drugs as the name implies, but there is a plan 
extend the existing laboratories to increase the production 
f simple and cheap drugs for use in government hospitals. 
The FDAC is headed by the Chief Pharmacist of the 
ederation who is responsible to the Minister/Commissioner for 
Several areas of comparison exist between the Drug Laws 
of Nigeria and the United States and they will be explored 
detail under the following titles: Product Standards, 
icing, Distribution and Restrictive Sale and Promotion and 
Comparison will be made between the two systems 
d major differences will be identified. 
roduct Standards 
The United States, through the Food and Drug Administration 
(FDA), establishes standards of safety and efficacy through 
a battery of pre-marketing testing which almost entirely 
the possibility of marketing products which are 
human consumption. Pre-marketing testing is done 
as required by the provisions of the "Notice of 
laimed Investigation New Drug (IND). Pre-marketing testing 
by the provisions of the New 
Before the application for the IND is filed with the 
assumed that all details about the pharmacology, 
biology, etc. of the new drug product, have been 
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The next step is to apply this knowledge in clinical 
beings. 
The New Drug Application requirement is in three phases: 
A period of human pharmacology, when investigations are 
to indicate toxicity, dosage, absorption, excretion 
in the body. 
A period of limited trial of the drug in patients with 
the disorder the drug is designed to treat. 
Phase III: 
Large scale trial on patients with the specific disorder. 
estimated that it takes at least sever-and-a-half 
Pharmaceutical Manufacturers Association - PMA -
said 10 years) from the period of gestation of a potential 
drug to final approval of the drug for marketing by the FDA. 
If tlEnew drug is an antibiotic, the FDA laboratory assays it 
determine that it has the required potency and safety and 
hat it meets certain other standards of quality. Each batch 
et antibiotic produced must be so certified.a 
Before the 1961 thalidomide disaster in parts of Europe 
Canada, only a safety requirement was imposed on new drugs 
tn the United States . After the disaster, efficacy requirement 
provisions of the Kefauver-Harris Ammend-
1962. This ammendment also, for the first time pro-
definition for "new drugs". 
In some instances, the Food, Drug and Cosmetic Act of 1938 
similar to the Nigerian Food and Drug Decree of 1974 which 
~empts al l drug laws enacted in Ni geria before 1974 . 
traPh 7 of t he Decree reads a s follows : 
No per~on ~hall manufacture ~or sale, a~y.drug 
specified in schedule 4----without obtaining 
a certifi cate from the commissioner that the 
premises in which the drug is intended to be 
manufactured and the conditions by and under 
which the manufacture is to be carried on 
are---sui table for ensuring that the drug 
will be s a fe for use . 9 
Jlaterials listed in schedule 4 are as follows: 
Liver Extrac t in all forms 
Insulin in all f orms 
Anterior pituitary extracts 
Radioactive isotopes 
Living va cc ines for oral or prenteral use 
Para-
Drugs prepared from micro-organisms or viruses , for 
patenteral use 
Sera and Drugs analogous thereto , for parenteral use 
Antibiotics for parenteral use . 
As seen in the above list , some of them are biologicals, some 
are biologica l extracts , one is a radioactive isotopes and 
•ome are ant i b iotics . The emphasis in the above regulation 
is on the 11 ••• premises in which the drug is intended to be 
It can be noted that the safety of the 
drug as regards its toxicity has not been mentioned . The 
requirement i n t he above regulation has been modified in 
of the Decree which will be discussed below. 
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The implication of the above law is that once the premises 
which the drugs are intended to be manufactured are certified 
the commiss ioner, the drug manufactured therein must be 
Safe in the sense that the drugs do not contain 
or filth" or any substance that would make them injurious 
The toxicity of any drugs sold by the multi-
companies is not at this time in question. 
heir integrity is not being -,·impugned; their experience in 
United States is enough to prevent any reoccurrence of 
"Elixir Sulfanilamide" disaster of 1936. However, the local 
janufacturers, particularly the indigenous Nigerian drug 
mpanies, operate within the same law. This is where there 
uld be potential problems. 
Paragraph 7(2) of the Food and Drug Decree states as 
No person shall sell any drug specified in 
schedule 5 bf this decree without first obtaining 
in accordance with the regulations a certificate 
of the commissioner that the batch from which the 
drug was taken is safe for use.11 
5 are as follows: 
Arsphenamine 
Dichlorophenarmine Hydrochloride 
Neoarsphenarmine 
Oxophenarmine Hydrochloride 
Sensitivity disc and Tablets 
Sulpharsphenamine 
ese are heavy metal compounds used as anti-infectives or 
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perhaps as anti-amebics. These drugs are not used extensively 
in Nigeria. In fact, they are not used much in the United 
States either. However, they are subject to as much safety 
requirements as are imposed on the manufacture of antibiotics 
in the United States. This might be due in part to the heavy 
toxicity associated with this class of drugs. 
It must be noted that this is the only group of drugs 
subjected to such a requirement in Nigeria . This is in 
ontrast to the United States law which only restricts such 
requirement to antibiotics due to possibility of variations 
in the active ingredients from batch to batch during manu-
facture. In Nigeria, antibiotics are not subject to such 
a requirement. 
The implication of this law is that all other drugs can 
be manufactured in Nigeria without a proof of batch to batch 
certification. Antibiotics manufactured by United States 
companies outside the United States are thus, not subjected 
to this requirement as long as the sale of such antibiotic 
in Nigeria would not be a contravention of the law of the 
country of manufacture. 
Paragraph 5 of the Food and Drug Decree states as 
follows: 
The 
No person shall label, package, treat, process, 
sell or advertise any food, drug ... in any 
manner that is false or misleading or is likely 
to create a wrong impression as to its quality, 
character and value, composition, merit or safety. 12 
Provisions of this paragraph may be subject to different 
kinds of interpretati'ons · · d ' · 1 depending on each in ividua s' 
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interest, Manufacturers may claim exemptions from the require-
the paragraph because of their apparent exclusion 
provisions of the decree. The government on the 
other hand, can claim that the words "quality, character, 
and value and merit" when taken together and read in the 
appropriate context , mean "efficacy'' or "effectiveness". 
This decree is analogous in context to the Federal Food, Drug 
and Cosmetics Act of the United States prior to 1962 when 
only a proof of safety of drugs was the only requirement. 
Effects of the Food and Drug Decree and the FDA Regulations 
The Food and Drug Administration regulations have a 
significant impact on the activities of the Drug companies 
in the United States, particularly in the periods after the 
1962 Kefauver-Harris Ammendments. Although the decline of 
new drug introduc tions and in the new drug approval rate in 
the United States cannot singularly attributed to the effects 
Of the ammendments , it goes a long way in explaining such a 
decline. Table 4 shows the decline in the introduction of 
Bingle new entity drugs in the United States from 52 in 1957 
to 15 in 1975. Table 5 shows a decline in number of total 
•PProved NDAs in comparison to number of I NDs submitted. 
In 1966, seven hundred and fourteen I NDs v. ere submitted 
!4? of them reached the NDA stages and only 40 of them were 
approved an approval rate of approximately 21 percent. 
one thousand one hundred and t wenty I NDs were 
submitted, only 92 of them went to the NDA stages, and only 
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TABLE 4 
DECLINING NUMBER OF NEW DRUG INTRODUCTIONS (1957-1975) 
No. of Single 
Year New Entity 
1957 52 
1958 47 
1959 65 
1960 50 
1961 45 
1962 24 
1963 16 
1964 17 
1965 25 
1966 13 
1967 25 
1968 12 
1969 9 
1970 16 
1971 14 
1972 10 
1973 17 
1974 18 
1975 15 
Pharmaceutical Manufacturers Association, 
Prescription Drug Industry s Factbook, 1976, p. 11 
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TABLE 5 
DRUG APPROVAL RATES IN THE U.S. (1966, 1970-1975) 
TOTAL NO. OF 
INDs 
714 
1120 
938 
976 
913 
842 
818 
TOTAL NO . OF 
NDAs 
147 
92 
99 
297 
146 
106 
132 
TOTAL NO . OF 
APPROVALS 
40 
51 
62 
57 
50 
85 
71 
approval rate beginning from 1970 is 7 percent. 
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PERCENT* 
APPROVED 
6 
5 
7 
6 
5 
10 
9 
erage approval rate for the three periods requested in this 
study between 1973 and 1975 is 8 percent. 
•Percentage is calculated based on total number of INDs and 
total number of approvals. 
FDA Annual Reports and FDA unpublished data. 
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•o of them were approved -- a rate of approximately four percent. 
In 1975, eight hundred and eighteen applications were submitted, 
l)2 of them reached the NDA stages and only 71 of them were 
a rate of 8 percent. 
There is also a considerable decline in number of firms 
operating in the United States from 127 in 1957 to 48 in 
1968.13 It has been estimated that the existing multinational 
companies will themselves grow and the increasing complexity 
of research and the demand for higher standards of safety and 
efficiency will raise the costs and encourage further amal-
pma.tions and takeovers. "By 1990 worldwide pharmaceutical 
research production and marketing will mostly be in the hands 
f some one or t wo dozen companies. About half of these will 
originated from the United States."14 
The present conditions in most developing countries and 
in Nigeria which is the dominant force in Black 
make it a fertile ground for pharmaceutical companies 
nations, 
The Hathi Committee15 has drawn up a list of essential 
for the basic needs of India. The list contains a 
of 116 drugs which are considered to be adequate for 
the medicinal needs of India. This view is shared by Mayler 
in his report published in the World Health Organizations 
Monthly Chronicle as follows: 
In many developing countries, the lack of national 
~ru~ policies allows foreign pharmaceutical firms 
0 influence the market demand to a considerable 
extent and to control the transfer of pharmaceutical 
technology when local production is undertaken by 
their s ubsidiaries or under licensing agreements . 
Furthermore , the regulations of the supply or 
prices of raw materials greatly influences the 
local pr oducti on of finished pharmaceutical pro-
ducts. Thw many developing countries remain 
dependent on foreign interests and spend a high 
proportion of their limited health resources on 
imported f i nished products or raw materials for 
local production of drugs, many of which are not 
suited to t heir real health needs , 16 
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It is not known how many drugs are sold in Nigeria, but 
f such a s t udy were conducted in Nigeria, the result would 
probably be simi lar to India ' s . It is estimated that only 
I small proportion of the order of one or two percent of the 
in developing countries would be sufficient 
cover basic pharmaceutical needs . 17 There are obviously 
ch more than 116 drugs on the Nigerian market . 
The price paid for these drugs is the next topic of 
SeYeral laws have been enacted with the sole aim of 
pricing procedures on the market. 
Sherman Antitrust Act of 1890 is the principal act that 
Others include the Clayton Act 
price discrimination, tying contracts, 
and etc.; the Federal Trade Commission Act 
established to enforce the provisions of 
le Clayton Act; and the Robinson-Patman Act of 1935 which 
Prohibits the granting of different prices to different 
commodities of like grade and quality, where the 
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effect of such practice is a reduction in competition . 
Generally, United States wholesalers ' and manufacturers' 
prices are not controlled. At retail level however, some 
eentrol exists, particularly, through cost control in the 
atate medicaid programs.1 8 In some European countries, a 
product cannot be registered if the price is unreasonable. 
france and Italy have formally frozen prices on pharma-
•eutical products. Others have ordered a price roll-back. 
Economic considerations play a major role in the 
registration of drug products in many Europena countries. 
for example, in several of the E.uropean countries, a product 
cannot be registered if the price is unreasonable. This is 
•xpected to be a major consideration in the United States 
when the National Health Insurance becomes a reality. 
In Ni geria, the consideration for registration of drugs 
s basically safety. Economic considerations are of low 
riority except when the government initiates competitive 
idding for drug sales among drug companies. 
The Price Control Board has not been very effective in 
dealing with rising prices of commodities in Nigeria.19 
!he government has, however, taken reactionary steps during 
xtreme price hikes by the various industries, particularly, 
he food industry . Roll-backs are recommended where prices 
are found to be unjustifiably high. So far in the pharma-
ceutical i ndustry, no price controls have been ordered and 
it . 
is highly unlikely that there will be significant controls 
n the Pharmaceutical industry at some future time. 
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In Ni geria, as in many other places, the pricing of drugs 
is affected by the method of buying, which does in turn, 
suggest resale values . The process commonly used by the 
Nigerian Army, which is a major drug purchaser, is a competi-
tive bidding system called "tender". Using its monopsony 
power, the government can and does set price limits on drug 
products in t he Nigerian drug market . Drugs obtained through 
~ender are given duty-free certificates and their resale prices 
are often much cheaper, comparatively.20 
Some multinational companies have taken advantage of 
lack of adequate price control regulations in the developing 
countries where prices of many drugs have increased by more 
than 100 percent in the last few years. 21 
The me t hod of transfer-pricing adopted by some multi-
national drug companies is another problem which developing 
nations such as Nigeria have to contend with. In Colombia, 
South America, certain tranquilizers were sold at 4,000 
to 4500 perc ent higher than alternative world market prices. 
In Iran in 1960s , intermediate bulk chemicals sold at between 
38 and 1000 percent higher than in developed nations where 
the bulk chemicals were manufactured. The price of the 
intermediate chemical would obviously have an effect on the 
ice of dosage forms. 
Distribution and Restrictive Sale 
The method of distribution and the control on drug 
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products depend mainly on what type of drug is under consi-
eration. Three classes of drugs will be discusseds 
Oyer-the-counter (OTC) Drugs 
-
These are drugs that are made available directly to the 
;urchaser without prescription. Controls imposed on such 
drUgs are similar to those imposed on the distribution of 
commodities under the provisions of the Uniform Commercial 
Code (UCC). The potential danger posed by this class of drugs 
has been minimiz ed by the "?-point label" required on all 
G!C drugs in the United States. The ?-point label is as 
followss 
1. the name of the product. 
2. the name and address of the manufacturer, packer, 
or distributor. 
J. the net contents of the package. 
4. the established name of all active ingredients and 
quality of other ingredients whether active or not. 
5. the name of any habit-forming drug contained in the 
preparation. 
6. the cautions and warnings needed for the protection 
of the user. 
?. adequate direction for safe and effective use.22 
OTC drugs are available through many outlets where commodities 
are sold. Th ey are available at supermarkets, pharmacies and 
etc. However, some OTC ·1 bl products are made ava1 a e to the 
Ublic exclusively through pharmacies. This group of drugs 
are also known as OTC ethicals". They are not promoted to 
'the Public. 23 
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The distribution of OTC drugs in Nigeria is through various 
nvenient outlets such as supermarkets, patent medicine stores, 
,.und-trucks and, of course, pharmacies. Patent medicine 
stores and sound trucks are similar ±n their practice except 
trucks are mobile forms of patent stores. The 
sound trucks usually go from one place to the other selling 
drugs. The patent medicine stores, according to Egboh,24 
have out-numbered pharmacies more than ten-fold; and they are 
engaged in selling all kinds of drugs including those which 
are available only under a doctor's prescription. 
There are no regulations controlling the sale of OTC 
drugs in Nigeria. No provision is made in the Nigerian Food 
f!ld Drug Decree for thecontrol of the distribution of any 
If' these drugs, and for that matter, there is no provision 
W.de about this class of drugs in any of the Nigerian laws. 
It is assumed, however, that manufacturers, particularly, 
foreign manufacturers, will conform to the requirements of 
~he regulation ~ of their home countries to control the sale of 
over-the-counter drugs. 
lrescription Drugs 
The distribution of prescription drugs is carried out 
pharmacies and physician ·offices. But as Mr. Egboh 
out, they are being sold over-the-counter by Nigerian 
Pl.tent medicine stores.25 
The 1951 Durham/Humphrey Ammendment to the Food, Drug and 
2!smet· A ic ct categorizes the kinds of drugs that may be dis-
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pensed by the pharmacist only on the prescription "of a 
practitioner licensed by law to administer such drugs". All 
iuch drugs must bear the legend - "Cautions Federal Law pro-
hibits dispens ing without prescription. 11 Hence the term, 
•legend drug" in reference to this class of drugs. 
Other requirements of this ammendment are as followsa 
1. It prohibits refilling of such prescription without 
expressed authorization of the prescribing physician. 
2. It provides for oral or telephone prescriptions of 
legend drugs. 
3. It provides for oral or telephone authorization of 
refills of legend drug prescriptions.26 
In Nigeria, through the provisions of the Dangerous Drug 
6!l, the pharmacist, physician, dentist, and the veterinarian 
the authority to handle prescription drugs which are 
Q;al.led "poisons" and classified into six parts: 
I. Crude dangerous drugs such as raw opium, coca leaves 
and Indian Hemp (Marijuana). 
II. Prepared opium. 
III. Medicinal Dangerous Drugs (with the exception of 
Cocaine and marijuana, all drugs listed in this 
part are derivatives of opium). 
IV. External Trade in dangerous drugs. 
V. Trade in new Drugs. 
VI. General. 
ordered on items in Parts I and II is as followsa 
(a) No one other than a registered pharmacist shall 
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sell poisons included in parts I and II.27 
On part III , it says that these drugs can only be obtained -
(a) 
(b) 
On signe d order by qualified persons, 
on prescription by those who are qualified by this 
Act (doctors, dentists and veterinarians). 
On part IV (trade in new drugs), it says as followss 
or 
(a) ~o person shall sell or import poisons included 
in part IV unless he or she is a registered 
pharmacist, 
(b) a person holding a license to import part IV 
poisons. 28 
Parts V and VI are in essence a repetition of the regulations 
ln parts I and IV. 
It is not known how these classifications are arrived 
at. But, with them are a list of do's and don'ts which in 
the final analysis are saying exactly what the United States 
Durham/Humphrey ammendment is saying, viz: that certain 
drugs cannot be dispensed to the public by the pharmacist 
unless by prescription written by qualified individuals who 
have been certified to do so. 
What these regulations prohibit, in brief, is the sale 
Of dangerous drugs such as morphine, heroin and marijuana 
(particularly those drugs which the United States would 
classify as schedule ' II drugs), unless they are on prescription 
written and signed by authorized individuals. Obviously, 
118.rijuana and heroin are out of place in this list. It is 
certainly not the intention of the Nigerian legislators to 
elude marijuana in the category of drugs which can be 
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lspensed by the pharmacist on prescription only.* The 
effects of the Durham/humphrey ammendments on the States is 
two-fold. Apart from reducing the incidence of illicit 
traffic in drugs, particularly those with abuse and misuse 
otential, it sets limits on the distribution of these drugs 
through legitimate channels by limiting the number of allow-
able prescription refills and requiring more extensive record-
ieeping. 29 
The Pharmacy Practice Act is not as clear in its focus 
as the Durham/Humphrey Ammendment. Its effects on the phar-
maceutical industry is not quite apparent. However, it can 
e concluded from discussions in Chapter IV, that this law 
is not being adequately observed. 
Controlled Drugs 
As indicated earlier, legal restrictions on the distri-
bution of a drug depends to a large extent, on the character-
istics of the drug in question. Controlled Substances are 
perhaps the most restricted commodities in any country, whether 
lgeria or the United States. 
There have been massive efforts to control Narcotics and 
ther dangerous drugs through treaties, protocols and inter-
ftational convent ions. The emphasis has been on the restriction 
t the production of opium to medical and scientific needs. 
•the Provisions of the Indian Hemp Decree supports this 
contention. 
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he United States has participated in all conventions, treaties 
and protocols since 1909. 
Nigeria participated in the convention of 1961 (Single 
Convention on Narcotic Drugs) for the first time as an inde-
pendent nation.JO At this convetion it was decided that 
nations which at that time "permitted quasi-medical use of 
opium ... and coca leaves", shall take, within a period of 
25 years (beginning from 1961), steps to eliminate such pra-
ctices.31 
Three Acts stand prominent in Nigeria, that deal with 
the manufacture, sale and distribution of narcotic drugs. 
These are as follows: 
1. The Dangerous Drug Act 
2. The Controlled Substances Act and 
J. The Food and Drug Decree. 
!he Poison and Pharmacy Act provides guidelines for the phar-
macists in the process of carrying out his duties within the 
boundaries of the law. 
Dru Acts DDA 
This Act lists some 100 drugs which are subject to res-
trictions in the areas of importation, exportation, sale and 
iatribution. 
ortation and Ex ortation 
Import Certificate or the Export Authorization must be 
Obtained from the Comptroller of Customs before such import 
and Distribution 
Since the sale and distribution of drugs are mostly 
effected by the pharmacist, the control of such is under 
guidelines set by the Poisons and Pharmacy Act. Under its 
provisions, a pharmacist musts 
1. Ensure that a precription for controlled drugs 
is genuine. 
2. Not dispense the drug more than once unless it 
is so specified by the prescribing physician. 
J. Make a record of the sale and keep such a record 
for at least two years. 
Among other restrictions imposed on the physicians as regards 
the prescription of controlled drugs, he (the physician) 
shall not be authorized to prescribe a medicinal dangerous 
drug for his or her own use". 32 
But for this restriction on the physician, there is a 
striking similarity between the provisions of the Nigerian 
erous Dru Act and the United States Comprehensive Drug 
use Prevention and Control Act of 1970. While some states 
Jl'Ohibit such practice, the general rule in the U.S. is that 
a physician may wri~e prescription for schedule II drug for 
ia personal use provided he is doing so "in good faith 0 .33 
The ~ covers drugs such ass morphine and its deri-
meperidine and related substances and methadone and 
•lated compounds. By the United States classification, most 
ot these drugs belong to Schedule II. 
e Controlled Substance Act of 1 68 CSA 
This decree was enacted in 1968 to deal specifically, 
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with the importation, sale and distribution of amphetamine 
and amphetamine-containing products. However, it was repealed 
by the enactment of the Food and Drug Decree of 1974. 
Food and Drug Decree of 1974 
-
The Food and Drug Decree (FDD) replaces many of the drug 
in Nigeria. Controlled Substances are dealt with under 
provision of paragraph J of the decree which says1 
Except as authorized by the regulation, no person 
shall i mport into Nigeria or export therefrom, 
manufacture, sell, distribute or cause to be dis-
tributed (whether as samples or otherwise) any of 
the drugs specified in schedule II of this decree.34 
Schedule II drugs are those which are classified under schedule 
Controlled Substances Act of the United States. 
Part A of Schedule II of the decree consists of the 
DET, DMHP, DMT, ISD, Psilocybin, STP, DOM and Tetrahydro-
It also includes the Amphetamines and derivatives, 
drugs, and all preparations containing some 
of amphetamine. ' 
But for the inclusion of the amphetamines 'Jm this _section 
list could have been referred to as an extract of the 
nited States schedule I drugs, with some minor addition. 
Part B of the devree deals with the following class of 
gss 
1. 
2. 
Sedat ives and hypnotics - barbiturates 
Non-barbiturate sedatives and hypnotics - glutethi-
mide methyprylon, etc. 
J. Skeletal Muscle Relaxants - Meprobamate 
4. Tranquilizers e.g. the phenothiazines 
5. Central Nervous System Stimulants - Caffeine 
6. Adrenergics e.g. Ephedrine and its salts 
7. Artificial Sweeteners such as Cyclamtes* 
!he list includes other drugs such as cobalt preparations, 
metallic tin and its compounds, potent antibiotics such as 
chloramphenicol and its preparations and many others. 
The controls on these drugs are similar to the controls 
imposed on drugs listed under the Poisons and Pharmacy Act. 
The classification seen above consists of drugs that 
can be classified under Schedule I through V of the United 
States CSA depending upon the potential for misuse and abuse 
of the particular drug in question. Many of the drugs listed 
on the other hand, are not subject to the control of the 
eontrolled Substances Act of the United States, for example, 
cyclamates have been banned in the United States; Ephedrine 
and its salts are not under the provisions of the CSA, and 
l'affeine is widely sold over-the-counter. 
In most of the drug laws, there appears to be an overlap 
n the restrictions imposed on importation, exportation, 
Manufacture, distribution and etc. of all kinds of drugs with 
the exception of OTC drugs which apparently are not subject 
to any kinds of restrictions. More confusing is the attempt 
to classify the controlled drugs and separate them from non-
-See App d. . en ix for complete list 
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controlled, legend drugs. For . example, the idea behind the 
splitting of Part A and Part B of schedule II of the FDD into 
two groups and subjecting these t wo groups into identical 
legal restric tions is not clearly understood. It is known 
that Part A is a list of highly abused drugs which are grouped 
into schedul e I of the United States CSA. To subject this 
group of drugs to the same standards required of drugs in 
Part B is i nappropriate. 
It can be seen that there are only minor differences 
between the CSA of the United States and the provisions of 
the Nigerian FDD and the other two Acts in the control of 
the distribution of narcotics in both countries. It appears 
that the Nigerian law is, in part, an extract from the United 
States law with only minor additions which, when taken together 
litake the Ni gerian law on controlled drugs rather more con-
servative and more stringent. 
Mr. J. Pink* has said that the "escalation of drug 
legislation by a "leap-frogging motion" probably arises from 
countries see ing protections enjoyed by other countries (and) 
clamouring for even better protection in their own (countries) 
without recognizing the debit effects that go with them. 11 35 
The "debit effects" in this case can be hypothesizeda 
1. It i s not certain that Nigeria has adequate resources 
(manpower and financial capital) to monitor and 
establish an effective control of the industry with 
an adviser to Wellcome Foundation Ltd. (U.K.) 
matters affecting the pharmaceutical industry. 
the result that some of the laws passed are never 
enforced. 
2. Some of the laws are not appropriate to the pre-
vailing conditions in Nigeria, particularly in cases 
such as the restrictions imposed on distribution of 
caffeine and the adrenergics which in many cases are 
sold over-the-counter in the United States. 
3. There is less incidence of drug abuse and misuse 
in Nigeria than there is in the United States and 
such controls are unnecessary. 
Promotion and Advertising 
With the exception of the law that specifies that detail 
aen have to be qualified in pharmacy, not legislations have 
been passed to control the promotion of drugs in Nigeria. 
However, the advertisement of drugs is controlled through the 
provisions of paragraph 3 of the Food and Drug Decree. It s~ysa 
Save as otherwise provided, no person shall: 
(a) advertise to the general public any food, cos-
metic, or device as a treatment, preventative 
or cure for any of the diseases, disorders, or 
abnormal physical states specified in schedule 
I to this decree. OR 
(b) sell any food, drug ..• that is represented on 
the label or is advertised to the general public 
as a treatment .•. for any of diseases •.. spe-
cified in schedule I.* 
The blanket prohibition on the advertisement of drugs 
Used in the treatment of the diseases . listed in schedule I 
*See A PPendix .. 4, for complete list of diseases in schedule I. 
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is rather broad. It implies, for example, that drugs used 
in the treatment of common colds can be advertised provided 
they do not contain antihistaminics, which incidentally, are 
also used in the treatment of hay fever. Neo-synephrineCR), 
w~ich may be used in combination with other drugs for the 
treatment of bronchial asthma, cannot by implication, be 
advertised. Rheumatic Arthritis is another ailment listed in 
aehedule I. Obviously, it is not the intention of the legis-
lature to prohibit the advertisement of aspirin and aspirin-
centaining drugs which are widely used in the treatment of 
r~eumatic arthritis. The inclusion of gastrointestinal 
111.cers in the list may also be questioned since there is a 
wide application of antacids in the management of this disease. 
lany of the drugs in the categories mentioned are widely sold 
~er-the-counter in Nigeria. 
Alternatively, it is not clear why many diseases are 
from the list. Malaria, emphysema, bronchitis, 
diseases and many others are not listed. It is 
"Plied that drugs used in the management of these diseases 
flan be advertised. 
There are certainly many loopholes in this particular 
'Plrt of the Food and Drug Decree which make it very difficult 
understand and difficult to enforce. The effect of this 
the manufacturers can be theorized. 
The Nigerian law against misbranding is analogous to the 
ited States law of 1906 which prohibits adulteration and 
Paragraph 5 of the FDD states that: 
No person shall:-
label, package, treat, process, sell or advertise 
any food, drug, cosmetic or device in a manner 
that is false or is likely to create a wrong 
impression as to its quality, character, value, 
composition merit or safety. 
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It is apparent from the typical drug advertisement seen in 
the course of the research that manufacturers may be cir-
cumventing the provisions of this law by failing to give 
proper direct ions for the use of the drugs just as they did 
after the enactment of the Federal Pure Food and Drug Law of 
1906.)6 Roche's advertisement of Valium(R) in the United 
States and in Nigeria is a typical example of the activities 
of the drug companies. In the Nigerian advertisement, Roche 
promotes only all the attributes of the drug and merely refers 
readers to the packing slip for more information. In the 
United States the same company not only wrote out information 
concerning the attributes of the drug, but also included the 
contraindications, warnings, precautions, dosage, management 
Of overdose and how the drug is supplied. All these are 
required by the United States FDA and the FTC. Moreover, 
the advertising contains reference to Roche's complete pro-
duct information guide for more information. 
Another example is the Merck, Sharp and Dohme's advertise-
ment of Aldomet (R) in both countries. In the United States 
»aper, there is practically complete prescribing information; 
but in Nigeria, the information made available is sparse and 
incomplete. 
Even in the United Kingdom, which in most instances, 
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serve as a model for marketing activities in Nigeria, the 
United Nations Conference on Trade and Development reported 
thats 
" •.• recent investigations •.. showed that several 
TNCs (Transnational drug companies) were selling 
several hunrlred drugs which had been withdrawn 
from the American market by the Food and Drug admi-
nistration as "lacking evidence of effectiveness." 37 
An example of this is seen in the case of an American drug 
company which makes a brand of chloramphenicola 
The manufacturer has had difficulties with the 
United States authorities for years over the unde-
sirable side effects of the drug and has paid over 
a million dollars in damages for failing to warn 
of these effects. Yet it continues to promote 
this drug heavily in the United States and other 
countries; in the U.S., however, it is required 
to warn against six conditions in which the drug 
should not be used, in the Federal Republic of 
Germany and Australia only one, and in several 
developing countries, none at a11.38 
Industries in Nigeria have enjoyed major concessions 
from the government in form of incentives such as tax relief, 
low tariff rates for imported products, etc. But recently, 
several changes have been made and are being made which 
threaten those incentives in some cases or eliminate them 
completely in others. The pharmaceutical industry is not very 
threatened at this time, but their incentives have been dras-
tically reduced. 
The marketing of drugs is controlled by several govern-
ment agencies in the United States, on the contrary such a 
responsibil ity is charged to one agency in Nigeria called 
the Food and Drug Advisory Council ctreated only in 1974. 
The Nigerian pharmaceutical law, particularly as 
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by the provisions of the Food and Drug Decree, 
etreates an illusion that there is adequate control over the 
activities of the drug industry when in fact, it is full of 
loopholes that provide incentives for unscrupulous marketing 
practices. 
Although there is no evidence of widespread illegal 
practice by the drug companies in Nigeria, conditions are 
condusive for such practice, particularly when competition 
becomes more vigorous. Such evidence has been found in other 
developing countries where drug laws are as relaxed as they 
are in Nigeria. Prices have been found to be excessively 
high in countries of South America where conditions are similar 
Nigeria's. 
In many cases, Nigeria's drug laws are subject to various 
interpretations depending on individual~s interests and in 
instances, the laws are ahead of the United States drug 
in level of stringency. 
It has been found that Nigerian drug laws in some insta-
are analogous to the United States laws in the late 1930s 
conditions were similar to the conditions in Nigeria at 
The Food and Drug Decree's classification of drugs into 
Schedules is one of the most confusing aspects of the law. 
It has different unrelated criteria for each group of drugs 
or medical supplies. In this case, the United States laws 
much clearer and more logical in sequence. 
In general, however, the laws in both countries are 
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similar in context, and the same trend in escalation of 
pharmaceutical laws by a "leap-frogging motion" in other 
countries, particularly in the United States, is currently 
in motion in Nigeria and catching up to the United States is 
a matter of time. 
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VI. SURVEY OF PHARMACEUTICAL COMPANIES 
It was recognized that because this survey dealt primarily 
with sensitive areas of pharmaceutical business practice, there 
might be a problem in securing response from people in the 
industry. 
Consequently, care was taken to design the questionnaire 
in such a way that respondents would not feel threatened, nor 
would they provide self-serving answers. Thus, the questions 
were designed to ensure that responses could be obtained 
from the participants without sacrificing any vital informa-
tion in the process. 
Appendix 4 presents a copy of the questionnaire used in 
this study. The first seven questions were designed to pro-
vide a profile for the responding companies in both countries, 
particularly in determining the type of personnel in charge 
Of their Nigerian operation, and also in determining their 
Bales volume in both countries for three consecutive fiscal 
Jears. It was also designed to enable readers to know the 
current status of individual company's level of operation in 
areas of manufacturing. For companies which do not currently 
engage in manufacturing (and they are presumed to be many), 
reasons for such action were asked. 
The questions were also designed to determine what 
companies produce what products and what individual companies' 
leading products are on the Nigerian market. 
79. 
The next four questions (#8 through 11), were included 
in order to determine how much concern the companies have 
tor product registration in Nigeria. They were also designed 
to understand how much emphasis they place on the testing 
of products prior to marketing in order to compare their 
responses with that portion of the Nigerian law which deals 
with this issue. Responses to these questions would provide 
an insight into the pharmaceutical companies' operations in 
Nigeria vis-a-vis the government regulations. 
The succeeding six questions were included in order to 
measure the comparability between number of attempts by the 
pharmaceutical industry to introduce new drug products in 
both countries to the number of approvals in both countries. 
Responses received would provide information on the preference 
of the manufacturers in introducing new drugs. When the 
number of attempts are compared to the nuniber of approvals, 
it will be possible to determine the relative difficulty in 
getting products approved based on the knowledge of the laws 
in both countries. 
A knowledge of the number of United States Food and 
Drug Administration unapproved drugs currently sold in Nigeria 
by the industry would provide answers to the desirability of 
introducting products in Nigeria where the pharmaceutical laws 
are more relaxed. It will also provide answers to possible 
enticing marketing opportunity that prevails under such 
relaxed conditions. 
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The rest of the questions are designed to determine how 
the Unite d States fares with regard to trade concessions which 
at the moment only the United Kingdom enjoys. 
Answers to a question on how the registration and drug 
introduction laws of both countries are comparable with each 
other would certainly provide a confirmation concerning what 
has been empirically known for a while. 
Out of the sixty-five questionnaires mailed - fifty-two 
in the United States and thirteen in Nigeria - only six were 
returned fully or partially filled out for a response rate of 
approximately nine percent. 
Fourteen respondents wrote back refusing to participate 
in the s tudy for various reasons. Some of them referred all 
questions about their operations in Nigeria to their European 
headquarters. However, these headquarters never responded 
either. 
Some of the letters written by the non-participants 
included information that indirectly answers some of the 
questions raised in the questionnaire. For example, some 
companies have reduced their operations in Nigeria and have 
resorted to merely exporting to that country as a result of 
the government policy of having forty percent participation 
in all foreign investments in Nigeria. Others indicated that 
their operations in Nigeria are in the preliminary stages 
and therefore they could not contribute anything of major 
Bi.cn-.·r· 0
"
1 icance to the study. Some companies stated flatly 
that they do not make such information public as a matter 
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of corporate policy. 
From the six responses obtained, profiles of individual 
respondents will be made and where responses are incompletely 
supplied, i nformation about the particular company will be 
tilled in, bas ed on further research . A synopsis of the 
eompanies' responses to these questions will be made with 
latent awareness of the limitations imposed by low response 
rate. 
The foll owing sections present results by questions (see 
Appendix J for a copy of the survey instrument used). 
Company Profile 
? 
One of the responding companies is a subsidiary of a 
large corporation with diversified operations. Its operation 
is international in scope and has sales in the billion dollar 
range world-wide . It lists its world-wide sales of $400 
million in Medical Supplies for this company for fiscal year 
1975. It reports that it is against company policy to report 
Bales by i ndividual countries. It does not have a manufacturing 
facility i n Nigeria because of the Nigerian government regu-
lations and the country's political instability. It lists 
its major products in Nigeria as vitamins and prenatal 
Vitamin supplements. It is also involved in marketing of 
antibiotics to a lesser proportion. 
Another respondent is a relatively small cmpany with 
Projected pharmaceutical sales of $190 million in the United 
States for the current fiscal year. It lists projected sales 
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of $1 million in Nigeria for the same period. The respondent 
for this company is the Area Director for Nigeria, himself 
based in the United States headquarters. It too does not 
engage in any manufacturing in Nigeria. It indicates that 
Nigerian policy of participation in foreign investments in 
Nigeria is particularly responsible for its action. It is 
involved in the sales of antidiarrheals (its number one 
product in Nigeria), oral contraceptives, neuroleptics, anti-
spasmodics and antinauseants - all in order of decreasing 
importance. 
The third company is one based in the Southeastern United 
States. The person in charge of Nigeria is the Director of 
Operations for Middle East and Africa. It is a company which 
specializes in Cough and Cold Medicines in both countries 
under consideration. It lists other products sold in Nigeria 
as muscle relaxants, gastrintestinal analgesics, antidiarrheals 
and digestives. It does not report sales both in the United 
' States and in Nigeria. However, sales in the United States 
are in the hundreds of millions of dollars. This company 
does not manufacture pharmaceuticals in Nigeria because "sales 
(in Nigeria) are nat large enough to support a factory." 
The fourth company is a relatively small one based in 
North-Eastern United States. Sales volume reported shows 
a consistent decline over a three year period. It has its 
headquarters in Europe and it indicates that its operations 
in Nigeria are controlled through the European head office. 
The headquarters never responded to requests for information. 
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Its products are exported to Nigeria and it deals primarily 
in local anesthetics in the Nigerian market. 
The fifth respondent is the Public Relations Officer for 
the entire company. He represents a large company based in 
the North Eastern United States. He states that sales are 
not broken down by product class - a system very unusual in 
the pharmaceutical industry. It also indicated that its sales 
in the various overseas countries are not made public. It is 
a company with a relatively large operation in Nigeria. 
It does not manufacture its products in Nigeria because, 
says the Public Relations Director, "the market is currently 
adequately supplied." Its major products in Nigeria are 
antibiotics, appetite stimulants, anthelmintics, antihyper-
tensives and lastly, antiarrythmics. 
The sixth and the last company which responded has its 
headquar ters in New York City. It is highly involved in the 
Nigerian market. It has a $4 million factory opened recently 
in Lagos, Nigeria. It is highly specialized in the production 
and sale of antibiotics. It is also involved in other areas 
Buch as in anthelminthics, antiseptics, vitamins and anti-
diarrheals - in that order. The responding person is the 
Divisional Manager who is based in Lagos, Nigeria. His was 
the only response received out of the thirteen questionnaires 
Jllailed to Nigeria. He too did not make available his company's 
Bales figures from the Nigerian market. 
The r esponses received were from pharmaceutical companies 
With Wide variety of therapeutic class of drugs. All the 
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responding companies are international in scope. Most of them 
engage in exportation of drugs to Nigeria. Only one of them 
has a manufacturing facility in Nigeria. Only one of them 
listed sales volume in the United States over the three 
periods r equested for. One other listed sales in both countries. 
Five of the six companies do not manufacture pharmaceu-
ticals in Nigeria, some for economic reasons and some for po-
litical and legal reasons. 
GOVERNMENTAL RESTRAINT ON MARKETING 
Approval of Drugs before Marketing 
The Nigerian Government through the provisions of the 
Food and Drug Decree of 1974 requires that all companies 
obtain governmental certification before marketing. Four of 
the five companies responding to this section of the question-
naire indicated that their companies do get approval from the 
Nigerian Government before marketing their products. One 
indicated that it does not have to obtain such an approval, 
a practice which is inconsistent with Nigerian law. Three 
reasons may be attributed to this practice& (1) The company's 
responding officer is the Public Relations Director who may 
not know what the situation is like in Nigeria, but has to 
respond to the questionnaire perhaps because of pressure from 
superior officers in the company; (2) The company is deviating 
from normal practice because of an apparent lack of adequate 
enforcement of this portion of the pharmaceutical law; 
(3) The company is taking advantage of the law which specifies 
that drugs approved for sale in the country of manufacture 
may be sold in Nigeria but not before obtaining a license to 
to so. Careful analysis of the company's answers to the re-
maining questions, however, supports the conclusion that the 
latter t wo of thethree reasons enumerated above best explain 
the company ' s actions . 
Company's Liaison Officer with the Government 
In t he United States , most drug companies, it is presumed, 
have public relations and government relations officers who 
serve as l iaison between the company and the government. 
This by i tself emphasized the importance of rapport between 
companies and the government. It is even more important in 
areas where approval of drug products for marketing are desired. 
One of the companies indicated that the distributing 
firm in Nigeria acts as the liaison between the company and 
the government. Two companies indicated that they do not 
have an officer on their staff and two others indicated that 
they do. 
It can be suggested that: (1) These companies, parti-
cularly those who do not have such officers on their staff 
simply cannot afford the "luxury" of keeping such a staff 
on their payroll in Nigeria; (2) Some other company personnel 
in the company is responsible for such activities and therefore 
it will be a waste of employees• time and the company's money. 
However , it all boils down to one thing: that product 
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registration in Nigeria to those companies may not be of 
major concern. 
,tests Required on Products Before Marketing in Nigeria 
The Nigerian Food and Drug Decree requires only the 
proof of safety before a drug can be approved for marketing. 
However, the United States through the provisions of the 
Food, Drug and Cosmetics Act requires the proof of safety 
as well as efficacy before a product can be approved for 
marketing in the United States. 
The safety requirement is embodied in the series of 
pre-marketing testing which all potential new drugs go 
through in the United States. This question is asked as 
follows: 
(a)--- -toxicology 
(b)-- --clinical 
(c)---- efficacy 
(d)-- --safety 
(e)----stability 
(f)----other 
This question was asked in order to find out if the 
Pharmaceutical companies do conform to the requirements as 
specified in the Food and Drug Decree. It is designed to 
determine the standard of quality demanded of the drug 
industry as understood by them. As demonstrated in Chapter 
IV., the Food and Drug Decree consists of many loopholes that 
give room for unethical practice by some in the industry who 
87. 
may desire to do so. 
General agreement on the types of tests required of 
respondent would be a positive indication that they, at 
least, understand the law, and in all probability they would 
abide by it. 
One of the responding companies indicated on the question-
naire that clinical, efficacy, stability and other tests 
besides toxicology and safety are performed. Possible tests 
that may fall under the "other" category couldbe any or all 
of the following: terratogenic, bioavailability, pharmaco-
kinetics, etc. 
The Nigerian based respondent listed the followings 
toxicology, efficacy, safety, stability and other tests 
except clinical which he indicated is performed "sometimes". 
Other companies either did not respond or indicated on the 
questionnaire that data were not available. One of the 
respondents indicated that no tests were required as long 
as "clinical support is available from elsewhere." 
It can be seen from the first case above that "safety" 
and "toxicology" are not indicated as any of the tests 
required on potential drug products in Nigeria. The latter 
company (the only response from Nigeria), indicated that all 
tests except "clinical" (which is performed "sometimes"), 
are performed on its products before marketing. 
It can be seen from these responses that there is no 
general agreement among the participating companies on the 
kinds of tests which have to be performed on potential 
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new products in Nigeria. In contrast, as demonstrated in 
Chapter IV, these tests are embodied in a battery of clinical 
and animal testing as required by the provisions of the 
Investigational New Drug (IND) and the New Drug Application 
(NDA) in the United States. 
From these responses, these is evidence to suggest a 
general lack of understanding of the various drug laws of 
Nigeria among the respondents, particularly, those laws that 
deal with drug manufacturing. Such a lack of understanding 
might be explained as follows& 
1. Nigerian laws do not clearly delineate tests that 
have to be performed on potential new drugs and 
therefore such decisions are dependent on the indus-
try's ethical values. 
2. Nigeria's health delivery system cannot afford the 
"luxury" of such tests and some of the drug companies 
recognize this and therefore perform such tests as 
they deem fit. 
Rate of Drug Approval in Both Countries 
Companies were asked about the approval rates of drugs 
in both countries in order to determine if conditions are 
such that international drug companies would be encouraged 
to introduce drug products in Nigeria before doing so in the 
United States. 
Out of the three which responded to the questions, one 
indicated that out of four applications submitted in the 
Period between 1974 and 1976, three were approved and two 
of the approved drugs are actually on the market. Another 
one stated that out of four submitted, all four were approved 
for marketing and all four were actually on the market. The 
Nigerian-based responding company stated that nine applica-
tions were submitted and all nine were approved for marketing 
in Nigeria. Six of these products are currently being sold 
in Nigeria. 
An even more limited response rate was received regarding 
United States approval. One company stated five applications 
were submitted to the Food and Drug Administration during 
this period, only one of them which is currently on the 
market was approved for marketing. 
None of those who responded to the first set of questions 
about approval rate in Nigeria also responded to the latter 
three about the United States approval rate. This makes it 
difficult to make the comparison desired. The lack of res-
ponse to either one set of questions or the other is not likely 
to be a happenstance - except in the case of the Nigerian 
respondent which believed that the answers to the second 
set of questions could only be supplied by the headquarters. 
The approval rate in Nigeria is better than 90 percent 
for the three companies which supplied this information. 
Over the three year-period, a total of seventeen applications 
Were made, sixteen of these were approved, and a total of 
twelve products out of the sixteen approved are currently 
on the market. This is a success rate of approximately 70 
Percent between the development of new drug products and the 
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actual marketing in Nigeria. 
As seen from Chapter V, Table 4 of this study, the number 
of new drugs introduced into the United States market has 
declined from 400 in 1957 to 87 in 1968. Seventy percent 
of all new discoveries never make it beyond the laboratories. 
This study has found that high approval rates were achieved 
in Nigeria. However, limited evidence obtained for the 
companies' United States operations are simply inconclusive. 
United States Unapproved Drugs in Nigeria 
Questions 18, 19 and 20 of the questionnaire are designed 
to deal with the marketing of FDA-unapproved drugs in foreign 
countries, particularly Nigeria. One of the respondents 
indicated that out of the four or five such drugs in foreign 
markets, three are in Nigeria. None of the three was comple-
tely developed in the United States. "Some work on each was 
done in the United States." Another one of the respondents 
stated that "specific data (on unapproved drugs) were not 
available (but the number of such drugs) was believed to be 
few." None of them, it indicated, is on the Nigerian market, 
and none was developed in the United States. One other 
company indicated that no United States unapproved drug is 
in any foreign market. 
!._cceptability of United States-Supplied Data 
Two of the responding companies indicated that data 
obtained from and analyzed in the United States are satis-
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factory to the Nigerian officials "most of the time". 
The responses of these companies suggest that information 
provided on specific drugs in the United States are readily 
accepted by the Nigerian officials. However, limitations 
imposed by low response rate makes it very difficult to be 
conclusive. 
Comparison Between the Two Systems 
This is the only question responded to by all the parti-
cipants and there is a general agreement that new drug 
introduct ion legislation is more difficult in the United 
States than in Nigeria. 
VII. CONCLUSION 
General Differences 
The United States, when compared to Nigeria, has appro-
ximately three times the population , thirteen times the 
physical size, fifty times the Gross National Product and is 
several t imes greater in technical and scientific advancement. 
The United States is approximately 200 years older than Nigeria, 
but both gained -their independence from the United Kingdom. 
Nigeria's present general level of development is comparable 
to the United States in the 1930s, particularly in areas of 
pharmaceutical laws. 
Life expectancy in Nigeria is estimated to be about 40 
years compared to about 72 in the United States. Nigerians 
are afflicted with preventable diseases such as malaria, 
tetanus, meningitis, diarrhea, cholera, and so on while the 
United States is afflicted with physiological dysfunctions 
and disorders reflective of their life expectancy. 
Twenty-nine of the 50 states in the United States surpass 
Nigeria in the number of pharmacists, while 27 states have a 
greater number of physicians, and all 50 states have more 
dentis ts . The United States surpasses Nigeria in per capita 
figures in all categories of health professions. 
M_edical and Pharmaceutical Practice 
The Nigerian native doctors play a powerful role in health 
93. 
care de livery. But the people are becoming more sophisticated 
in the ir health care demands and are seeking care from less 
primitive sources (physicians, dentists, pharmacists, etc.), 
where a scientific approach is more prevalent. 
There is considerably less distinction between the pra-
ctice of the Nigerian physicians and pharmacists and their 
counterparts in the United States; but relations between these 
two groups are just as subtle. Although there are clear 
distinctions in the statutory limits on the practice of either 
profess ion, there is some overlap in their practice as seen 
in this study. It has been suggested in this study that 
there may be flaws in the enforcement mechanism of the laws 
enacted to guide the practices of these professionals. 
Evolution of Pharmaceutical Laws and Practice 
Although pharmaceutical laws and practice evolved in 
both countries in different time frames, the general develop-
ment took place in similar forms. In both countries, the 
Pharmacy profession was subjected to intimidation; in Nigeria 
by the national government until 1969, and in the United 
States by the medical profession at much earlier times. 
The laws have developed through evolutionary means in 
the United States, but in Nigeria, the pace has been in fact, 
almos t r evolutionary at certain points in history. Laws have 
been enac ted in the United States mostly as a result of 
traumatic national episodes (e.g. elixir sulfanilamide) or 
international experiences (e.g. thalidomide). On the contrary, 
94. 
in Nigeria laws have been enacted mostly as a result of major 
trends in pharmaceutical laws of the United Kingdom or the 
United States. 
Government Controls 
The controls imposed on the pharmaceutical industry's 
activities the world over are escalating in a "leap-frogging" 
motion. The escalation is greatest in the United States 
where most of the world production and consumption of drugs 
are carried out. 
Although drug consumption levels in Nigeria are insigni-
ficant when compared to the United States, the same trend in 
escalat ion of drug laws is shaping up gradually. However, 
the drug laws enacted are full of many loopholes which could 
make the enforcement of these laws very difficult. 
They also contain many confusing sections that make the 
laws difficult to understand. Says SCRIP in its comments 
about section 1(1)(c) and section 4(b) of the Food and Drug 
Decree that "while one may not sell an article of food which 
consists wholly or in part (inter alia) of "filthy, disgusting, 
rotten or diseased substance", it would appear that the only 
restriction for cosmetics are filth, decomposition and foreign 
matter. A cosmetic which contains a "disgusting" substance 
seems to be OK. " 
Similar comments can be made regarding safety require-
ments imposed by the Food and Drug Decree. It appears that 
as long as the premises in which drugs are manufactured are 
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clean, the safety of the drugs is guaranteed. 
I n the United States, the control of the production and 
distribution of drugs is charged to several government 
agencies; but in Nigeria only one agency of the government 
is responsible. 
Although there is no evidence of widespread illegal 
practices by the pharmaceutical industry, conditions such as 
unenforc ed price laws, lack of adequate controls on advertising 
materials , inadequate controls on manufacturing of drugs, are 
conducive to such practices. These conditions are similar 
to those existing in some of the developing nations of South 
America where evidence of illegal and unethical practices 
have been seen. 
ATTITUDES OF PARTICIPANTS 
The six respondents represent only a small section of the 
pharmaceutical industry in Nigeria. Most of the respondents 
and indeed many of the companies operating in Nigeria are 
only engaged in the preliminary stages of potentially large 
marketing operations and therefore appear to be reluctant 
to supply needed data for fear of giving out trade secrets. 
Many of the respondents do not have manufacturing faci-
lities and operate only by importing products from overseas 
countries - using the services of distributors. Generally, 
the re sponding companies have a reserved feeling about 
making large capital investments in Nigeria because of the 
Political climate and also because of the incessant search 
by the government for regulatory forces on the Nigerian 
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industrial front. Others see a hope in the Nigerian market 
particularly because of the recent surge in business, but 
will wait and watch until the time is ripe when conditions 
become sufficiently promising to warrant a local capital 
investment. 
There are wide insonsistencies between the drug laws of 
Nigeria as seen in previous chapters adn the responses of the 
participating companies. These inconsistencies suggest that 
there is general lack of understanding of parts of the Food 
and Drug Decree of 19?4. 
From the responses obtained, it appears that new drug 
introduc tion in Nigeria is of no major concern to the drug 
companies. Overall approval rate in the United States for 
the three periods requested is approximately eight percent 
for the entire industry compared to a rate of more than 90 
percent for the companies which responded. 
At least two of the responding companies indicated that 
they are marketing some United States FDA unapproved drugs 
in foreign markets. One of the two indicated that it has 
three such products on the Nigerian market. All the 
respondents agreed that new drug introduction legislation 
is much easier in Nigeria than in the United States. 
Although there is a significant difference in the appro-
val rates of drugs in the United States and Nigeria, the 
number of companies that participated in the study has made 
it difficult to make any conclusive report. However, it can 
be suggested that approval rates in Nigeria appear to be 
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higher. In addition, all respondents perceive drug intro-
duction legislation to be less stringent in Nigeria. 
RECOlVIMENDATIONS FOR FURTHER STUDIES 
This study has been hampered by a low response rate to 
the questionnaires. But its value cannot be underestimated 
for the reason that it opens up several areas that can be 
investigated upon much further and at a broader scale. 
Further studies can be embarked upon as case studies on 
selected companies that enjoy the confidence of the investi-
gator. 
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LETTER OF INTRODUCTION 
~ 99 , 
UNIVERSITY OF RHODE ISLAND 
KINGSTON, R. I. 02881 
College of Pharmacy • Department of Pharmacy Administration • 401-792-2735 
oear Mr. 
All f acets of the health care industry, particularly the 
pharmaceutical industry, are constantly reminded of the controls 
imposed by government. 
In order to measure the impact of some of these statutory and 
regulatory provisions on drug product marketing in the domestic 
and foreign markets, a study is being conducted by the University 
of Rhode Is l and Department of Pharmacy Administration. 
Since the principal investigator for whom this study is a 
thesis proj ect is a Nigerian national, the comparisons are between 
the United States and Nigeria. It is particularly signifieant that 
this resear ch is being conducted during the implementation phase 
of the Th ird National Development Plan of Nigeria. 
Your cooperation and response will help to make this a mean-
ingful and useful study, the report of which might provide insight 
into and focus upon the nature of the existing conditions in the 
two countries under consideration. 
Pleas e be assured that every measure will be taken to assure 
confiden t i ality of responses. Names are solely for tabulation pur-
poses and participants will not be identified · in the thesis. 
Loo~ing forward to receiving the stamped, self-addressed re-
return ~ve•lope containing your completed questionnaire very soon. 
Should you have any question, please do not hesitate to write 
~ call e ither signer of this letter. 
Thank you. 
Sincerely 
~~~~. 
fessor and Chairman 
Enclosures 
Ph.D. 
Sincerely, 
· 1l-~ 'L.- MJ~AILL'~f r 
Tunde Adenodi, B.S. 
Graduate Teaching Assistant 
Appendix 2 
REMINDER LETTER 
UNIVERSITY OF RHODE ISLAND 101. 
KINGSTON, R. I. 02881 
College of Pharmacy • Department of Pharmacy Administration • 401-792-2735 
January 21, 1977 
Dear Mr. 
re: Questionnaire about U.S. & Nigerian Drug Laws 
We are reminding you about the questionnaire that was mailed 
to you on December 28, 1976. 
Since the analysis of responses to the questions raised is es-
sential to the conclusion of the study, it is important that we re-
ceive the completed questionnaire. 
If you have any doubts about any of the questions raised, 
please comment on such questions and procede to the others. It 
will serve to enlighten us on the validity of such questions. 
We will be looking forward for your response. 
Sincerely, 
a .~ 
Norman A. Campbell, J.D. ,Ph.D. 
Professor aud Chairman 
Tunde Adenodi 
Graduate Teaching Assistant 
Appendix J 
QUESTIONNAIRE 
103. 
1. Name of company~----------------------~------------~ 
2. Name of respondent (optional) 
J. Total domestic sales (Pharmaceuticals): 
A) Current fiscal year (projected) $ 
B) Current fiscal year -1 $ 
C) Current fiscal year -2 $ 
4. Total Nigerian sales (Pharmaceuticals), if applicable: 
A) Current fiscal year (projected) $ 
B) Current fiscal year -1 $ 
C) Current fiscal year -2 $ 
5. Does your company manufacture pharmaceuticals in Nigeria? 
Yes No 
6. If answer to question #5 is "No", why is your company not 
manufacturing in Nigeria? 
A) no marketing potential 
B) government regulations 
C) political instability 
D) not a company objective 
E) reason unknown 
7. What are the five leading therapeutic classes of drugs sold 
in Nigeria by your company? (Please list in rank order, 
the highest assigned a value of 1, and the least, a value 
of 5.) 
3. 
------------------
4. 
~----------~----
5 · ----~-----------
8. Does your company have to obtain Nigerian government approval 
before marketing its products in Nigeria? ___ Yes ___ No 
9. Does your company have a governmental liaison officer 
responsible for product registration in Nigeria? 
__ Yes ___ No 
103. 
1. Name of company---~~---~-------~~~------~~ 
2 . Name of respondent (optional) 
J. Total domestic sales (Pharmaceuticals): 
A) Current fiscal year (projected) $------~-
B) Current fiscal year -1 $ _______ _ 
C) Current fiscal year -2 $ ______ _ 
4. Total Nigerian sales (Pharmaceuticals), if applicable: 
A) Current fiscal year (projected) $ 
B) Current fiscal year -1 $ 
C) Current fiscal year -2 $ 
5. Does your company manufacture pharmaceuticals in Nigeria? 
Yes No 
6. If answer to question #5 is "No", why is your company not 
manufacturing in Nigeria? 
A) no marketing potential 
B) government regulations 
C) political instability 
D) not a company objective 
E) reason unknown 
?. What are the five leading therapeutic classes of drugs sold 
in Nigeria by your company? (Please list in rank order, 
the highest assigned a value of 1, and the least, a value 
of 5.) 
1 • 
------------------
3. 
-----------------
4. 
---------~------
5. 
------------------
8. Does your company have to obtain Nigerian government approval 
before marketing its products in Nigeria? ___ Yes ___ No 
9. Does your company have a governmental liaison officer 
responsible for product registration in Nigeria? 
__ Yes __ No 
104. 
10. Are you required to conduct any tests on your products 
in Ni geria before distribution? ~Yes ~No 
11. If "yes" what tests are required? 
A) toxicology 
B) clinical 
C) efficacy 
D) safety 
E) stability 
F) other 
12. How many new products did you submit applications for the 
Nigerian government between 1974 and 1976? ______ _ 
13. How many of these products were approved for marketing in 
Nigeria? 
14. How many of these products are actually on the market? 
15. How many NDA's did your company submit to the US(FDA) Food 
and Drug Administration between 1974-1976? ______ _ 
16. How many of the products were approved for marketing? 
17. How many of them are on the U.S. markets? ____________ __ 
18. How many U.S. unapproved drugs are on any foreign market? 
19. Are any of the U.S. unapproved drugs on the Nigerian 
market? 
-------
20. How many of the U.S. unapproved drug products were 
21. 
developed in the U.S.? ______ _ 
Are data 
the U.S. 
A) 
B) 
C) 
on imported drugs obtained from and analyzed in 
satisfactory to the Ni gerian officials? 
all the time 
most of the time 
sometimes 
D ____ never 
22. How would you compare new drug* introduction and regis-
tration laws of both Nigeria and the United States? 
A) ___ more difficult in the U.S. 
B} __ more difficult in Nigeria 
C)_~no difference 
105 
23. Please check the statement below if you desire to get 
a copy of the result of investigation. 
I wish to receive a copy of the result of the investi-
gation. 
*New drugs are drugs which are new on the Nigerian market or 
new development for Nigerian patients. 
Appendix 4 
SCHEDULES 1 THROUGH 5 OF THE 
FOOD AND DRUG DECREE 
Food and Drugs 
SCHEDULES 
SCHEDULE I 
DISEASES, ETC. REFERRED TO IN SECTIO:>i 2 
Alcoholism 
Appendicitis 
Arteriosclerosis 
!Asthma 
'-BTood disorders 
C~ncer 
Cataract 
Diabetes 
Cholera 
Diphtheria 
Disorders of menstrual flow 
Disorders of prostate gland 
Dysentery 
Encephalilitis 
Enteric fever 
Epilepsy 
Erysipelas 
Filariasis 
Gallstones, kidney stone,;, and bladder stones 
Gangrene 
1974 No. 35 
Section 2 
Any genital or urinary di seases not mentioned eise,·.-here in this Schedule 
Glaucoma 
..._ Goitre Q1ay FeYer 
Heart disease 
Hernia 
High blood pressure 
Infective hepatitis 
Influenza 
Jaundice 
Kidney disease 
Leprosy 
Locomotor ataxis 
Loss of youth 
Measles 
Meningiti~ 
Mental conditions 
l\.111mps 
Nervousness 
Nutritional disorders 
I,/ 
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( >hc,;ity 
( )nchocl'rciasis 
Paralysis 
Plague 
Pleurisy 
l'11e11 rnon ia 
Poliornyditis 
Rahi(·s 
Hheunrntic fcn·r 
Schistoso111iasis 
SCHEI>ULE 1- coutinued 
Sexual impotrncc, bss of \·irility or sterility 
Slt:cpin~ sickness 
Smallpox 
Snake hitc 
Syphilis 
Tl'tanus 
Trad10111a 
T11ben.:11losis 
T11n1011rs 
Typhoid fcn-r 
Undulant fcn~ r 
Vlccrs of the gastro-intl'stinal tra..:t 
\'cncrl'al <liseas..:s 
Yaws 
Yellow frn:r. 
Scclio11 3 
D1wc;~ HEFE1rnw To I:--i SECTIOi\ 3 
Part.·/ 
DET 
D!\1 Ill' 
Di\IT 
LYSEHGlllE/1.!>D , l.SJ>-25 
:\lcscalinc 
paralil·xyl 
psilocinc, p~ilotsin 
P~Il.OC\"Uli\E 
(N, :'\-dietliyltryptamine) 
(3-( 1,2-dirnet hylhcptyl)- 1-hy<lrox: -7, 8, 9, 
1 () tct r:ihnlro-(i, 6, 1J-trimcthvJ-(, H-dibcnzo 
(h,9) pyr.an) · 
(N, :'\ -dimethyltrypta111inc) 
(- I·)-:'\, :\"-diet h yllyscrgami<lc ( J-lysc;·gic 
acid dil'thylamidl') 
(3, .f.. :'i -trimcthoxyphrncthyla111 i11c) 
(3-lil'\_\'l-1-h:dro.\y-7 , ~. 9, lfl-lc\1altydn1-
(1, (1 , 'l-triml'tliyJ-(,11-dibcnzo (h,J) pyran) 
( .\-( 2-dimcth _1· la111i11oct h yl)-+-h yd rnxy i11 
dole) 
(3-(2-di1nl'thyLnni1111l'thvl) imlol-.f.-yl dihy-
dn•gl'n phos l'h ;1 lt') 
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STP, DOl\I 
tctrahy<lrucannahin•ib, 
all isomers 
Ai\tl'llEl'MIJ:\E 
Dl:."XAl\IPltET,\!\llNE 
i\J F.TI IAi\I PllET:\;\I l :\E 
i\hrrtlYl.PJIE!':IDATE 
PHENi\IETRA7.l:\E 
!'HF.NCYCLIDl:\E 
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(Z-amino-1-(2. 5-Jimctho:.;y-4-mcthyl) 
phcnyl-prnpan<') 
1-hydruxy-3-p..:ntyl-fo, 7. 111. l!la-tctra-
hy<lro-6, 6, 9-trimcthy!-6-Il-dibt:nzu (b,<l) 
pyran 
( + )-2-amino- l-pitcnylpropmc) 
( + )-2-ami111>-l-phcnylprupJnc) ( + )-2-mcthylamino- l-p~cnylp1opane 
(2-phcnyl-2-(2-pipcridyl) act:tic aciJ, 
methyl est<'r) 
( 3-mcthyl-2-phen y I mor? holi n..:) 
{l-(1-phenykylohC':xyl) pi pet it.line 
Any synthetic C'ompoun<l or salt (however :.truLtural!y dcriveJ) uf 
Amphetamine or of any substance of the like nature ~ .-\m?hctar.1;nc. 
Part B 
Al\IOBARBJTAI. 
CYCl.OIJARilJT,\L 
GLUTETllll\llDE •• 
PENTOBARllITAL •• 
8ECOB.>\RU!TAI. 
Al\lfEl'R:\i\IO:SE 
J!AROITAL 
cthchlorvynol 
ETJIINA:\!ATE 
i\frrttOll:\;\!:\TE . . 
l\J F.TllAQL'Al.O:-<E 
:\ J ETI I YI .PllE:\011.\H flt TA!. 
MF.TllYPRYt.O;-.; •• 
l'HENOBAHUIL \I. 
P1rnAnno1. 
Sr A 
CouAt:r l'HEl'.\HATto:-is 
CY<.:l.IZINE 
SuLrttAi\IETI 1oxYnt .\Z t:S-E 
Su1.1•11,\n1 ~1ET1 1ox 1~ E 
A:-.llNOPYIU1\E :\;\!) Dtl'YRUNE 
An:cAH11no;\1 ,\I . 
CARllHO;\l.\l. 
llno:-.HSOVAI. 
(5-ethyl-5-(3-meth::lhu y!) barhit11ric aciJ) 
(5-( l-cyclohcxen- l-yl)-5-cthylbarbituric 
acid) 
(2-cthyl-2-methybmino- l-pht:n yi-prop-
ane) 
(5-cthyl-5-( 1-methylbut~·! ) 
(5-allyl-5-(1 mcthylhu: .\ l) bar!:iituric acid) 
{2-( d iethylami ne) p r<J p!r,}-the1, :mnc 
(5, S-dicthy!b :1rbit u~ ic a:::d) 
C'thyl-2-chlorO\·inyll .. h: :1 ~· ~-c.:rbi 11ul 
1-ct hyny lcyduhcx;, nu~ c.1.- bd111at l' 
2-mcthyl-2-propyl-l, : -p rnpJtH:Jiul :lic.ir-
bamate 
2-mcthyl-3-u-tolyl-+ (.; HJ- quinazolinonc 
5-cthyl-l-mcthyl-5-phc:n:: l-harbitut ic aci<l 
3, 3-<liethyl-5-mcthy!-2. +-pipc:idi0n 1: -
5-ethyl-5-phcnylbarbi: 1: iic a-: id 
1, 1-diphcnyl- l - I -(2-p ipeiidyl) mC't hanol 
(-)-1-dimcthybmirn:- l. 2-<liphrnyl<.:tha:i..: 
l\I1:.1·At.t.1c 'f1:--; A:-11> ir:; Co~11·ot.l'\1J~ 
l lEX.'lt"l I LOHOl'l IA:\ E 
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Part B - co11ti1111f rl 
fatPTEN (2-(P-hminophcnyl)-cthylglyt:irimi<le) 
l\·JF.Cl.OZINE 
DmuoNor. 2. 2-thiubis (4, 6-dichlorophenol) 
hl!PR.'\MINE 
EFOCAJNE 
KF.ONOV1 :.\I 
XF.NAzo1c Aero on XENAI.A:\IINE 
DITHLAZ:\l'\I::-iE IonmE 
CJILORPIIENTF.!UllNE 
CYCLA'.\J:\TES, CYCLOHEXYl.BJl::-;E A="<D THEIR DF.RIV:\TI\".ES 
COMPHF.TA!\tlNES 
CHLOR.\:\ll'!IENICOL .'L'ID ITS PREPAll.\TIO);S 
CAFFEINE • .,... 
EPHEDRIN ANO !TS. SALT 
SCHEDlJLE 3 
PUDLir.ATIO:-;s REFEHRED TO IN SECTION 5 
Pharmacopoeia Internationali:; 
Section S 
Any other pharmacopoeia published under the authority of a recognised 
medical or pharmac<:utical cou ncil of :iny country . 
SCIIED"CLE 4 
. / 
Dnucs n EFrnnrn To 1:-.; SEcno:-.; 7 (1) 
Liver extract in ::ill forms 
Insulin in ::ill form~ 
Anterior pituitary extracts 
Radioacti\·e i::otopcs 
Living vaccines for oral or parentcr:il use 
Sfclion i 
Drug;; prepared from micro-organisms or virusc~. for parenteral u.;e 
Sera and drugs analng"llS thereto, for parenteral use 
Antibiotics for parenteral use. 
SCHEDULE 5 
Ont.res HEFEHllED To IX SF.cTJoN 7 (2) 
Ar~phennmine 
Dichlorophcnar~inc hydrochloride 
Ncoarsphcnamine 
Oxophenarsli irw hydrochloride 
Sensitivity di~cs :ind tablets 
Su lpharspl1cn;iminc 
Section 7· 
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